Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 1 of 61   
 
Phase 2 Trial Evaluating the Safety and Tolerability of 
Intratumoral Injections of NanoPac®  with Standard of 
Care Therapy in Subjects with Lung Cancer  
 
Protocol Identifying Number: NANOPAC -2020- 01 
IND Sponsor: NanOlogy, LLC  
IND #: 147012  
Version Number: 4 .0 
Date: [ADDRESS_975085] OF ABBREVIATIONS  ................................................................................................................................................ 5 
SPONSOR SIGNATURE [CONTACT_1783]  .......................................................................................................................................... 7 
STATEMENT OF  COMPLIANCE  ....................................................................................................................................... 8 
PROTOCOL SUMMARY  ................................................................................................................................................... 9 
1 KEY ROLES  ....................................................................................................................................................... 14 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ............................................... 15 
2.1 Background Information  ...................................................................................................................... 15 
2.2 Rationale  .............................................................................................................................................. 19 
2.3 Potential Risks and Benefits  ................................................................................................................. 21 
2.3.1  Known Potential Risks  ....................................................................................................... 21 
2.3.2  Known Potential Benefits  .................................................................................................  21 
3 OBJECTIVES AND PURPOSE  ............................................................................................................................. 21 
4 STUDY DESIGN AND ENDPOINTS  ..................................................................................................................... 22 
4.1 Description of the Study Design  ........................................................................................................... 22 
4.2 Endpoints  .............................................................................................................................................. 23 
4.2.1  Primary Endpoint  .............................................................................................................. 23 
4.2.2  Secondary Endpoints  ........................................................................................................ 24 
4.2.3  Exploratory Endpoints  ...................................................................................................... 24 
5 STUD Y ENROLLMENT AND WITHDRAWAL  ...................................................................................................... 24 
5.1 Participant Inclusion Criteria  ................................................................................................................ 24 
5.2 Participant Exclusion Criteria  ............................................................................................................... 25 
5.3 Strategies for Recruitment and Retention  ........................................................................................... 25 
5.4 Participant Withdrawal or Termination  ............................................................................................... 25 
5.4.1  Reasons for Withdrawal or Termination  .......................................................................... 25 
5.4.2  Handling of Participant Withdrawals or Termination  ....................................................... 26 
5.5 Premature Termination or Suspension of Study  .................................................................................. 26 
6 STUDY AGENT  .................................................................................................................................................. 27 
6.1 Study Agent(s) and Control Description ............................................................................................... [ADDRESS_975086] Storage and Stability  ........................................................................................... 28 
6.1.4  Preparation  ....................................................................................................................... 28 
6.1.5  Dosing and Administration  ............................................................................................... 28 
6.1.6 Route of Administration  ................................................................................................... 29 
6.1.7  Dose Adjustments/Modifications/Delays  ......................................................................... 29 
6.1.8  Duration of Therapy  .......................................................................................................... 30 
6.1.9  Tracking of Dose  ............................................................................................................... 30 
6.1.10  Device Specific Considerations  ......................................................................................... 30 
6.2 Study Agent Accountability Procedures  ............................................................................................... 30 
7 STUDY PROCEDURES AND SCHEDULE  ............................................................................................................. 30 
7.1 Study Procedures/Evaluations  ............................................................................................................. [ADDRESS_975087] of Care Study Procedures  .................................................................................. 31 
7.2 Laboratory Procedures/Evaluations  ..................................................................................................... 32 
7.2.1  Clinical Laboratory Evaluations  ......................................................................................... 32 
7.2.2  Other Assays or Procedures  .............................................................................................. 32 
7.2.3  Specimen Preparation, Handling, and Storage  .................................................................  33 
7.2.4  Specimen Shipment  .......................................................................................................... 33 
7.3 Study Schedule  ..................................................................................................................................... 33 
7.3.1  Screening 33 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 3 of 61 7.3.2  Days of NanoPac Injection –  Day 1, week 4, week 8  ........................................................ 34 
7.3.3  Follow -Up Visits  ................................................................................................................ 35 
7.3.4  PRIM ARY ENDPOINT Study Visit (week 24, approximately 6 months)  ............................. 36 
7.3.5  Follow up visit week 38 and END OF STUDY WEEK 52  ...................................................... 36 
7.3.6  Early Termination Visit  ...................................................................................................... 37 
7.3.6  Unscheduled Visits  ............................................................................................................ 37 
7.3.7  Schedule of Events Table  .................................................................................................. 38 
7.4 Justification for Sensitive Procedures  .................................................................................................. 40 
7.5 Concomitant Medications, Treatments, and Procedures  .................................................................... 40 
7.6 Precautionary Medications, Treatments, and Procedures  ................................................................... 40 
7.7 Prohibited Medications, Treatments, and Procedures  ........................................................................ 40 
7.8 Prophylactic Medications, Treatments, and Proc edures  ..................................................................... 40 
7.9 Rescue Medications, Treatments, and Procedures  .............................................................................. 41 
7.10 Participant Access to Study Agent At Study Closure  ............................................................................ 41 
8 ASSESSMENT OF SAFETY  .................................................................................................................................  41 
8.1 Specification of Safety Parameters  ...................................................................................................... 41 
8.1.1  Definition of Adverse Events (AE)  ..................................................................................... 42 
8.1.2  Definition of Serious Adverse Events (SAE)  ...................................................................... 42 
8.1.3  Definition of Unanticipated Problems (UP)  ...................................................................... [ADDRESS_975088] .................................................................................................. 46 
8.4.5  Reporting of Pregnancy  .................................................................................................... 46 
8.5 Study Halting Rules  ............................................................................................................................... 46 
8.6 Safety Oversight  ................................................................................................................................... 47 
9 CLINIC AL MONITORING ................................................................................................................................... 47 
10 STATISTICAL CONSIDERATIONS  ....................................................................................................................... 48 
10.1 Statistical and Analytical Plans  ............................................................................................................. 48 
10.2 Statistical Hypotheses  .......................................................................................................................... 48 
10.3 Analysis Datasets  .................................................................................................................................. 48 
10.3.1  Missing Data  ..................................................................................................................... 48 
10.4 Description of Statistical Methods  ....................................................................................................... 48 
10.4.1  General Approach  ............................................................................................................. 48 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  .................................................................... 49 
10.4.3  Analysis of the Secondary Endpoint(s)  ............................................................................. 49 
10.4.4  Safety Analyses  ................................................................................................................. 49 
10.4.5  Adherence and Retention Analyses  .................................................................................. 50 
10.4.6  Baseline Descriptive Statistics  .......................................................................................... 50 
10.4.7  Planned Interim Analyses  .................................................................................................  50 
10.4.8  Additional Sub- Group Analyses  ........................................................................................ 51 
10.4.9  Multiple Comparison/Multiplicity  .................................................................................... 51 
10.4.10  Tabulation of Individual Response Data  ........................................................................... 51 
10.4.11  Exploratory Analyses  ........................................................................................................ 51 
10.4.12  Concomitant Medication  .................................................................................................. 51 
10.5 Sample Size  ........................................................................................................................................... 52 
10.6 Measures to Minimize Bias  .................................................................................................................. 52 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 4 of 61 10.6.1  Enrollment/ Randomization/ Masking Procedures  .......................................................... 52 
10.6.2  Evaluation of Success of Blinding ...................................................................................... 52 
10.6.3  Breaking the Study Blind/Participant Code  ...................................................................... 52 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ........................................................... 52 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................................. 53 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................................... [ADDRESS_975089]  ................................................................................................................... 54 
13.3 Informed Consent Process  ................................................................................................................... 54 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............. [ADDRESS_975090] POLICY  ....................................................................................................................... 58 
17  LIABILITY AND INSURANCE  .............................................................................................................................. 59 
18  LITERATURE REFERENCES  ................................................................................................................................ 60 
APPENDIX A: ECOG Performance Scale  ....................................................................................................................... [ADDRESS_975091] Lymph Node  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 6 of 61 MedDRA  Medical Dictionary for Regulatory Activities  
NCI National Cancer Institute  
NDA  New Drug Application (Marketing Application)  
PCA Precipi[INVESTIGATOR_715881] -free Survival  
pH Hydrogen Ion Concentration  
PI [INVESTIGATOR_715882] -emergent Adverse Event  
ULN  Upper Limit of Normal  
UP Unanticipated Problem  
VAS Visual Analog Score  
WBC  White Blood Cell  
 
 
  
lntratumoral lnjection of NanoPac in Subjects with Lung Cancer
NanOlogy, LLCProtocol NANOPAC-2020-01
Version 4.0
SPONSOR SIGNATURE [CONTACT_715945]: Phase [ADDRESS_975092] of Care therapy in Subjects with
Lung Cancer.
ProtocolNumber: NANOPAC-2020-01
Version Number:
Date: 7 July 2021:
IND Number: L470t2
Study Agent: NanoPac@ (sterile nanopa rticulate paclitaxel) Powder for Suspension
Sponsor: NanOlogy, LLC
[ADDRESS_975093] to the IND; in accordance with [ADDRESS_975094] to all activities related to the lND.
SIGNATURE4.0
Sponso/s Representative - Name [CONTACT_13693]:
Gere diZerega, MD
President & CEO, US Biotest, lnc.
6zrplDn non
6eredizereB. tJur 7. 2o!(lo:,[ADDRESS_975095]) July 7,202t
Signature [CONTACT_790]'s Representative Date
[ADDRESS_975096] the confidentiality of the document.  
The signature [CONTACT_114117] [INVESTIGATOR_411194]/her agreement.  
 
 
__________________________________________  __________________________  
Signature [CONTACT_789]    [CONTACT_1782]  
 
 
 __________________________________________  
Printed Name [CONTACT_789]  
  
[INVESTIGATOR_715883] -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 9 of 61 PROTOCOL SUMMARY  
 
Title:  Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of 
NanoPac ® with Standard of Care therapy in Subjects with Lung Cancer  
 
Précis:  In this open -label trial, 18 subjects with lung cancer will receive intratumoral (ITU) 
NanoPac ® (sterile nanoparticulate paclitaxel) Powder for Suspension via 
endobronchial ultrasound -guided transbronchial needle injection  (EBUS -TBNI).  
 
Eligible subjects include primary or recurrent non -resectable non-small cell lung 
cancer ( NSCLC ) or small cell lu ng cancer ( SCLC ), with primary or recurrent 
measurable disease limited to the tracheal, hilar, mediastinal, and peribronchial 
structures (lung tumors and lymph nodes) accessible through EBUS -TBNI, have a life 
expectancy of at least [ADDRESS_975097] cerebral metastases, ECOG ≤ 2, severe 
infection and other metabolic disorders, prior sensitivity/anaphylaxis to paclitaxel, or 
any other clinically significant comorbid disease that may limit the ability of th e 
subject to participate in the study ( e.g. significant cardiorespi[INVESTIGATOR_715884] ). 
 Subjects may receive concomitant standard of care intravenous ( IV) chemotherapy , 
radiation therapy , and/or targeted therapy  as required for their care.   
 
Subjects will be administered NanoPac on three  occasions , at a 15  mg/mL 
concentration 4 weeks apart , up to 20% of the total calculated tumor and lymph 
node volume to allow for up to a maximum volume of 40 m L per bronchoscopic 
procedure  (i.e. the total tumor volume that can be treated is 200 m L). Up to two 
pulmonary parenchymal lesions will be injected, along with the metastatic lymph 
nodes selected by [CONTACT_715900] -TBNI. The volume of Nano Pac to be delivered at all three 
injection procedure s will be estimated based on the tumor and lymph node volume 
calculation from CT imaging obtained at baseline.  At each injection visit, tumor size/s 
will also be measured using EBUS, and the tumor/s and node/nodal sizes recorded 
for comparison only.  The volume of Nano Pac injected, total and/or lesional, will at 
no time be increased beyond the maximum as calculated by [CONTACT_715901]( s). Delivery of NanoPac to the lesion may be via multiple 
injections/sticks to maximize the dispersal of Nano Pac throughout each individual 
lesion . 
 
NanoPac injections will be planned according to the following schedule:  
 
• Day 1 –  first injection, Week 4  – second injection, Week 8  – third injection.  
o Follow -up visits will occur 1 and 2 weeks following each injection ; 
o Additional follow -up visits will occur at Week s 12, 18, 24, and 38  ([ADDRESS_975098] injection) ; 
o End o f Study visit will occur at Week 52 ( [ADDRESS_975099] 
injection ). 
 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975100] scans by [CONTACT_715902] (monthly) throughout the study period . All 
imaging will be made available to the Sponsor . Any personal information that could 
identify the subject will be removed before images are shared with the Sponsor. 
Data will be reviewed for subjects independently and as a group during this review. 
Discussio n with the Investigator and the Sponsor Medical Director may be 
required/requested at any time by [CONTACT_1689]. In addition, the first three 
subjects will be enrolled singly and sequentially, and a safety review will be 
performed by [CONTACT_715903] w Committee ( SRC) (by [CONTACT_577]) after the first 
subject has undergone the 2-week follow -up visit  after their first administration of 
Nano Pac to confirm that the second subject may proceed to injection. This safety 
review process will be repeated for the second and third subjects in a sequential manner prior to opening general enrollment to the study . The SRC will also perform 
a safety review after each of the first three subjects has undergone the [ADDRESS_975101].  
 Blood samples will be obtained from subjects for pharmacokinetic (PK) evaluation o f 
paclitaxel in the systemic circulation and at set time points for flow cytometric (FCM) evaluation of immune markers. Tissue samples (biopsies) may be obtained at each 
injection prior to the administration of NanoPac to evaluate the presence of 
paclitaxe l in the tissue and for evaluation via immunohistochemical (IHC) staining for 
immune markers.  
 All subjects will undergo CT scan s within 4 weeks prior to start of treatment,  prior to 
each injection at Weeks 4 and 8,  and again at Week s 12, 18,  24,  38 and 5 2 (End of 
Study Visit). CT scans will be used to provide preliminary signs of the effect of 
NanoPac on the lesion(s) and nodes. The baseline redacted CT scan will be 
forwarded to the Medical Monitor for review/approval with the completed pre -
injection form prior to first injection for all subjects.  All imaging will be collected for the subject’s record and identifiers removed before images are shared with the Spon sor.  At the second and third injections the same volume/dose of Nano Pac will 
be administered to each lesion as was administered at the first bronchoscopic 
procedure.  
 
Subjects will be followed for a total of a year  after the first NanoPac injection; 
asse ssments during t his time will be primarily for safety (laboratory values, adverse 
events, concomitant medications , etc.)  during the first 6 months of the study , and 
information will be obtained to evaluate progression -free survival (PFS) using the 
RECIST [ADDRESS_975102] scans.  The assessments at 
Week 38 and Week 52 will provide additional information on PFS and overall survival (OS).  Subjects will also complete a quality of life ( QOL ) questionnaire (EQ -5D) prior 
to firs t injection of Nano Pac, and throughout the study  until the E nd of the Study at 
Week 52. Subjects will be grouped for review at study completion based on the 
number of treatments (bronchoscopic procedures) they received . 
 
Objectives:  Primary objective:  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 11 of 61  • To evaluate the safety and tolerability of NanoPac injected directly into lung 
cancer lesions and metastatic lymph nodes by [CONTACT_715904] -
guided injection on up to three  occasions, each occasion 4 weeks apart.  
 
 Secondary objectives:   
• PK evaluation - paclitaxel in the systemic circulation and in tissue samples ; 
• To evaluate effect on PFS and OS in this population ; 
• To assess changes in the treated lesion (and lymph nodes) via CT scan 
imaging .  
 
Endpoints:  Primary endpoint:  
• Safety and tolerability as demonstrated by [CONTACT_20721] (AE s), changes in 
laboratory assessments, physical examination findings and vital sign s. 
 
 Secondary endpoints:  
• Blood samples will be evaluated for paclitaxel levels at all clinic visits; tissue 
obtained at the second and third injection timepoints will be compared 
against baseline paclitaxel levels obtained from a pre -NanoPac sample taken 
prior to the first injection ; 
• PFS defined as change in tumor size classified using RECIST 1.1, metastatic 
disease, and death ; OS as determined by [CONTACT_715905];  
• Assessment of tumor response (dimensions, volume) as de termined by [CONTACT_715906], measured at baseline and Weeks 12 , 24, 38 and 52 ; 
o Any changes in characteristics of lesion/nodes as determined via CT 
scan.  
 Exploratory/Tertiary endpoints:  
• Changes in Eastern Cooperative Oncology Group ( ECOG ) Performance 
Status;  
• Changes in pain (as measured by [CONTACT_224968] [VAS])  in the first 6 
months of the study ; 
• Changes in Q OL as measured by [CONTACT_715907] -5D Q OL instrument;  
• Assess immune markers in the blood via FCM, and in the tissues via IHC  in 
the first 6 months of the study .  
 
Population:  Eighteen subjects with primary or recurrent non -resectable NSCLC or SCLC lung 
cancer, with primary or recurrent measurable disease limited to the tracheal, hilar, 
mediastinal, and peribronchial structures (lung tumors and lymph nodes) accessible 
through EBUS -TBNI. 
 
Phase:  Phase 2  
 
Number of 
Sites enrolling 
participants:  
 Up to five (5) 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 12 of 61 Description of 
Study Agent:  NanoPac® (sterile nanoparticulate paclitaxel) Powder for Suspension (“NanoPac”) at 
concentration of 15 mg/mL administered into the tumor within the lung via EUS -
TBNI . 
 
Study 
Duration:  The study duration is estimated to be  up to 36 months.  
 
Participant 
Duration:  The study duration is est imated to be up to [ADDRESS_975103] – Screening 
may occur up to one month prior to first injection.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 13 of 61 STUDY SCHEDULE  
 
  Screening6 Day 1  Week 
1   Week 4      Week 8          Week 
24 Week 
38 Week 
52 
NanoPac  Week 
2 NanoPac  Week 
5 Week 
6 NanoPac  Week 
9 Week 
10 Week 
12 Week 
18 (6 
months)  (9 
months)  (12 
months)  
Informed 
Cons ent X                             
History1 X                             
Physical Exam  X X     X     X         X     
Pain 
Assessment4 X X X X X X X X X X X X X     
QOL 
Questionnaire    X     X     X     X X X X X 
Vital Signs   X  X X X X  X X  X X X X X X  X X 
ECOG2  X  X      X      X     X X  X X X 
Clinical 
Laboratory 
Tests8,9 X X   X X   X X   X X X X   
PK Samples 
(blood)3   X X X X X X X X X X X X   
Blood FCM 
analysis    X     X     X     X X X    
Tissue (biopsy) 
for IHC and paclitaxel   X     X     X             
Imaging (CT 
Scans)[ADDRESS_975104] scan will be conducted as  part of the end of study 
procedures. Additional imaging may be performed at the Investigator’s discretion as per institutional standard of care  and all 
resulting images will be collected for the subject’s record.  
[ADDRESS_975105] for women of child- bearing potential at screening, W eek 12 and W eek 24. 
9       Clinical laboratory tests include hematology, chemistry, urinalysis and at screening includes serology  (Hepatitis A, Hepatitis, 
B, HIV).  
  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 14 of 61 1 KEY ROLES  
 
Medical Director  
Gere diZerega, MD  
President & CEO, US Biotest, Inc.  
Professor, University of Southern [LOCATION_004] Keck School of Medicine  
[ADDRESS_975106]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
[PHONE_12627]  
[EMAIL_7837]  
Study Director  
Shelagh Verco, PhD  
US Biotest, Inc.  
[ADDRESS_975107]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
[PHONE_13491]  
[EMAIL_12357]  
Medical Monitor  
Antony Verco, MD  
US Biotest, Inc.  
[ADDRESS_975108]., Suite 240, San Luis Obispo, CA [ZIP_CODE]  
[PHONE_12628] 
[EMAIL_7840]  
Laboratory – PK Samples  
Covance Madison Laboratories Bioanalytical (BA) Group  
[ADDRESS_975109], Madison, WI [ZIP_CODE]  
[PHONE_13492]  
 
Central Laboratory – Immunohistochemistry on Biopsies  
NeoGenomics Laboratories, Inc.  
Attn: Pharm a Services Department  
31 Columbia  
Aliso Viejo, CA [ZIP_CODE]  
Phone: 949 -445-7300 x7103  
 
Central Laboratory – FCM evaluation on whole blood  
NeoGenomics Laboratories, Inc.  
Attn: Pharma Services Department  
31 Columbia  
Aliso Viejo, CA [ZIP_CODE]  
Phone: 949 -445-7300 x7103   
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 15 of 61 2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
2.[ADDRESS_975110] to all activities related to the IND. Therefore, 
references to “Sponsor” hereafter in this protocol refer to US Biotest, Inc.  
Name [CONTACT_649653]:  
NanOlogy, LLC (NanOlogy) has produced a formulation of nanoparticulate paclitaxel,  identified as 
NanoPac® (sterile nanoparticulate paclitaxel) Powder for Suspension (NanoPac), which is the subject of this protocol. NanoPac, previously called Nanotax®, is manufactured using a Precipi[INVESTIGATOR_411197] (PCA) technique that employs supercritical carbon dioxide and acetone to 
generate paclitaxel nanoparticles within a well- characterized particle -size distribution. Following PCA, 
NanoPac is filled into a clear 60mL Type 1, USP, clear- glass vial (306 mg/vial) as a powder fill o f 
nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and 
sterilized by [CONTACT_411215]. Prior to administration at the hospi[INVESTIGATOR_307]/clinic, NanoPac will be 
reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chlo ride for Injection, USP, to form a 
suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP  to 
achieve the final clinical formulation. This reconstitution and dilution will occur at the clinical site’s Pharmacy.  
Noncl inical Summary:  
Nonclinical studies of intratumoral  (ITU)  injection of NanoPac in animal models of lung cancer have not 
been performed. However, NanoPac has demonstrated preliminary safety and efficacy when injected 
ITU in animals with solid tumors  and whe n administered as an inhalation therapy in animal models of 
lung cancer. Preclinical data is presented in the NanoPac Investigator’s Brochure.  
Two in vivo nonclinical pharmacology studies were conducted to determine the effects of ITU  delivery of 
nanopart iculate paclitaxel in a nude mouse xenograft model. Animals treated with NanoPac 
demonstrated significant reduction in tumor size ( p < 0.01 for all comparisons) and survival benefit ( p < 
0.01 for all comparisons) compared to vehicle -treated animals. NanoPac reduced mean tumor volume 
by 74.1% by [CONTACT_2006] 22 compared to vehicle; body weights for all groups remained stable or increased 
throughout the treatment phase.  
A GLP -compliant study (Study Number P -TR-06-2018) evaluated and characterized the toxicity and 
toxicokinetics (TK) of NanoPac following a single intraprostatic (ITP) administration into the prostate in 
rats. There were no test article -related findings in mortality, clinical or ophthalmological observations, 
organ or body weights, food consumption, hemat ology, coagulation or clinical chemistry. The death of 1 
out of 20 animals/dose group at 0 (control) and 2.9 mg/kg NanoPac w ere considered procedure -related , 
were likely due to a combination of local trauma of injection compounded by [CONTACT_715908] o f 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 16 of 61 paclitaxel in and around the injection site. At the terminal interval on Day 4, findings of necrosis with 
mixed inflammation and fibrin deposition were noted in the prostate, with mineralization (kidneys), 
mixed inflammation and fibrin deposition (urinary bladder, seminal vesicles and iliac lymph nodes) 
noted in the adjacent tissues. At the recovery interval on Day 28 (± 1), similar findings were observed, 
with partial/ongoing to complete resolution.  
The toxicity of NanoPac was evaluated following a single ITP dose in rats. In this non -GLP study  (Study 
Number P -TR-04-2016) , there were no NanoPac -related findings in the following parameters evaluated: 
mortality, clinical observations, body weights, food consumption, coagulation, clinical chemistry, or 
urina lysis. The death of 1 out of 10 animals/dose group at 8 and 16 mg/kg NanoPac on Day  [ADDRESS_975111] been caused by [CONTACT_715909], ureters, and kidneys. These deaths were considered due to a combination of the local 
trauma of injection  compounded by [CONTACT_715910].  
NanoPac administered by [CONTACT_715911]. Intraperitoneal (IP) administration of NanoPac has demonstrated less toxicity than IP Taxol, and 
increased survival and tumor load reduction with or without surgical debulking.  GLP and non -GLP single 
and multiple dose toxicity studies in rats and dogs, and an in  vivo proof -of-concept study of NanoPac in a 
mouse xenograft study were conducted via the inhaled route of administration. These studies 
demonstrated preliminary efficacy with toxicity as expected for the route of administration viz. minimal 
systemic effects due to lack of absorption across the lung parenchyma, and dose -responsive airway 
epi[INVESTIGATOR_715885] (inflammation, necrosis, fibrosis, 
pneumonitis).  
Clinical Summary:  
NanoPac has not previously been administered to the human lung via EBUS -TBNI . Two clin ical studies 
with NanoPac have been completed  – one Phase 2a study of ITP injection of NanoPac in locally -
advanced prostate cancer  and one Phase 1 study of IP NanoPac in patients with peritoneal malignancies . 
Additional data from these clinical trials is p resented in the NanoPac Investigator’s Brochure.  
Phase 2a Study in Prostate Cancer  
In this study of NanoPac focal therapy of prostate cancer (NANOPAC -2016 -02; [STUDY_ID_REMOVED]), ITP 
NanoPac was injected in ascending concentrations of 6, 10, and 15 mg/mL in an injection volume of 20% 
of the lobe of the prostate containing the dominant lesion . Subjects were followed for 4 weeks for 
safety and tolerability prior to prostatectomy.  The primary obj ective of the study was to evaluate the 
safety and tolerability of NanoPac . Sixteen subjects were enrolled and received study agent  according to 
the protocol. The majority of subjects experienced treatment emergent adverse events (TEAEs) as expected, but with minimal frequency, severity, and relation to NanoPac. T he most frequent TEAEs 
occurred in the system organ class of gastrointestinal disorders, most of which were in the 6 mg/mL   
cohort . There was no obvious dose -response relationship with respect to the frequencies of the TEAEs. 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 17 of 61 Compared to Taxol, no dose -limiting toxicities (DLTs) or toxicities typi[INVESTIGATOR_715886], thrombocytopenia, peripheral neuropathy, and hypersensitivity reactions such as 
angioedema and urtica ria were reported. There were no serious adverse events (SAEs), deaths, or 
discontinuations from the study due to adverse events (AEs).  
 
Pharmacokinetic (PK)/pharmacodynamic (PD) modeling of Taxol- induced neutropenia suggests toxicity 
is related to the du ration and extent of systemic exposure to paclitaxel which correlates with a threshold 
plasma paclitaxel concentration of ≥ 42.7 ng/mL . In contrast, plasma paclitaxel concentrations observed 
after administration of NanoPac  in clinical study NANOPAC -2016 -02 had C max values of 19 to 20 ng/mL 
recorded at the earliest sample (the 1 -hour timepoint ). In addition , and b y comparison, a standard 
intravenous (IV) dose of paclitaxel of 175  mg/m2 BSA administered over 3 hours resulted in a C max of 
3,650 ng/ml (Paclitaxel Drug Label Information – Teva), about 192x higher than the mean NanoPac 
concentration achieved in the 15  mg/mL cohort  at [ADDRESS_975112] injection of 
NanoPac into the prostate would result in limited systemic exposure to paclitaxel and should therefore 
result in only low -grade and transitory AEs is therefore supported by [CONTACT_715912].  
Due to the small size of the study and the natural slow rate of progression of prostate cancer, the 
majority of the individual outcomes showed no changes o r variable results across the three 
concentrations of NanoPac over 4 weeks of exposure to NanoPac. The mean volume of the prostate 
increased between the  time of injection and prostatectomy, likely due to the local inflammatory 
reaction generated by [CONTACT_715913] . Reflecting this, the sexual health as measured by [CONTACT_715914] ( SHIM ) deteriorated over the course of participation, which can be explained by [CONTACT_715915]. Notably, the mean total 
Gleason score remained stable in the 6 mg/mL and 10 mg/mL cohorts, and improved in the 15 mg/mL 
cohort, implying a possible dose -response relationship. Preliminary efficacy was demonstrated by ( 1) 13 
of 16 subjects had stable or improved Gle ason scores (all in the 15 mg/mL cohort); ( 2) 11 of 16 subjects 
had stable or improved proportions of cancer lesion tissue defined as adenocarcinoma (6 of 11 subjects 
showed reductions in proportion of tissue identified as adenocarcinoma while 5 showed no change); 
and (3) 11 of 16 subjects had stable or improved levels of invasion by [CONTACT_715916] (4 of the 11 
subjects showed less invasion into the surrounding tissues, while 7 subjects showed stable disease).  
Overall, the primary objective of the study was achieved, i.e. preliminary evidence indicates that direct injection of NanoPac into the prostate appeared  safe and tolerable.  
Phase 1 Study in Peritoneal Malignancies  
A Phase 1 study of intraperitoneal (IP) NanoPac in subjects with peritoneal malignancies, HSC#[ZIP_CODE] ([STUDY_ID_REMOVED]) was completed. The results of this study were published by [CONTACT_715917] 2015 in the 
journal Cancer Chemotherapy and Pharmacology . 
 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 18 of 61 HSC#[ZIP_CODE] was  a dose -escalating study evaluating IP administered Nanotax (the same drug as NanoPac, 
but under a different name) at doses of 50 -275 mg/m2 given every 28 days until disease progression or 
unacceptable toxicity occurred. Twenty -two patients were enrolled i n the study. IP administration of 
NanoPac did not lead to increases in systemic toxicity over that typi[INVESTIGATOR_715887]. No  
Grade 2 or higher neutropenia and/or Grade [ADDRESS_975113] response assessments were made in 16 of the 21 subjects. 
Four subjects were assessed as stable or had no response and 12 subjects had progressive disease. Five 
of 21 patients with advan ced cancers survived longer than 400 days after initiation of IP NanoPac 
treatment.  
Phase 2 Study in Ovarian Cancer  
Clinical trial NANOPAC -2016 -01 entitled, “Phase II Study of Four Dose Levels of Intraperitoneal 
NanoPac® plus IV Carboplatin and Paclitaxel  in Patients with Epi[INVESTIGATOR_715888],” was a phase 2, open -label, dose -finding trial, designed to evaluate preliminary 
safety and efficacy of four concentrations of IP NanoPac plus six cycles of IV carboplatin and IV  paclitaxel 
in patients with platinum -sensitive recurrent stage III epi[INVESTIGATOR_76296]. Subjects had NanoPac 
instilled directly into the peritoneum just prior to surgical cytoreductive close. A total of 10 subjects 
were enrolled into the study, seve n into the 100 mg/m2 cohort and three into the 200 mg/m2 cohort.  At 
least one TEAE was reported in 10 of 10 subjects. A total of 108 TEAEs were reported for both NanoPac 
concentration cohorts (80 TEAEs in 100 mg/m2; 28 TEAEs in 200 mg/m2). Although statis tical 
comparisons were not performed, there was no apparent association of the number of TEAEs with the 
dose administered. There were no TEAEs which led to subject discontinuation, however one TEAE 
occurred in each concentration cohort which lead to a fata l outcome; both were attributed to 
progression of disease. The majority of TEAEs occurred in the gastrointestinal System Organ Class (SOC) 
in the 100 mg/m2 and 200 mg/m2 dose groups and were mostly nausea and vomiting in both groups. 
Fourteen TEAEs were gr aded as severe or worse; 10 occurred in the 100 mg/m2 dose group, and four 
occurred in the 200 mg/m2 dose group. Thirty -seven TEAEs were considered possibly related to IP 
NanoPac, 27 events occurred in five subjects in the 100 mg/m2 dose group, and 10 events occurred in 
two subjects in the 200 mg/m2 dose group. Overall, a 66% progression free survival (PFS) occurred at [ADDRESS_975114] -IP NanoPac, with further improvement noted at 18 months after treatment, supported by 
[CONTACT_715918] -125 and lack of additional cancer- related symptoms six months or more after 
treatment.  
Study in Pancreatic Mucinous Cystic Neoplasms  
Completed clinical trial NANOPAC -2017 -01 entitled “A Trial Evaluating Escalating Doses and the Safety of 
Intracy stic Injection of NanoPac in Subjects with Mucinous Cystic Pancreatic Neoplasms,” was an open -
label, dose escalating trial injecting NanoPac into a single mucinous cystic pancreatic neoplasm 
(diameter ≥ 1.5 cm and ≤ 4 cm) via endoscopic ultrasound -guided f ine needle injection (EUS -FNI). 
Subjects were followed for cyst response to therapy as shown by [CONTACT_9661], and concentration of 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975115] -injection. In total, 20 subjects were enrolled into the study; [ADDRESS_975116] one TEAE, with a total of 99 TEAEs 
reported. No deaths or DLT occurred. The majority (91.9%) of TEAEs were of either mild or moderate 
severity, and 4% were severe (4% of unknown severity). Across all treatment gro ups, the most 
frequently reported TEAEs (32.32%) involved the SOC of Gastrointestinal Disorders. Five SAEs were 
reported in five subjects. Of the five events, three were severe (breast cancer, abdominal pain, 
organizing pneumonia), and two were of moderate  severity (gastric obstruction, hepatic 
encephalopathy). Only one event of gastric outlet obstruction was considered probably related to study 
medication. Although statistical comparisons were not performed, there was no apparent association of 
the number,  severity, or relationship of TEAEs with the dose/concentration or number of injections 
administered. Analysis of the response rate of subjects demonstrated that the majority of subjects  
demonstrated stabilization or improvement in calculated volume and/or longest diameter of the cyst. Of 
these subjects, 55.6% showed improvement at Week 12, increasing to 70.6% at Week 24. In addition, 
50% of subjects had a reduction in calculated volume of ≥ 30% at both Week 12 and 24. When 
comparing changes at Week 12 comp ared to Week 24, 62.5% of subjects showed a further reduction in 
calculated volume compared to Week 12, occurring after single or double injections. Further, of those 
subjects who demonstrated increases in calculated volume at Week 12 compared to baseline,  75.0% 
showed a decrease in calculated volume at Week 24 compared to Week 12, one of which occurred after 
one injection and five after two injections of the 15 mg/mL concentration of NanoPac.  
Ongoing Clinical S tudies  
Ongoing clinical trials injecting NanoP ac direct ly into lesions include the following:  
1) Pancreatic tumors via endoscopic ultrasound guided fine needle injection (EUS -FNI) (NANOPAC -
2016- 05; [STUDY_ID_REMOVED]) .   
 
2.[ADDRESS_975117] -line treatment of 
NSCLC in combination with cisplatin in patients who are not candidates for potentially curative surgery 
and/or radiotherap y.  Similarly, both Taxol and ABRAXANE are FDA-approved first -line treatments of 
locally advanced or metastatic NSCLC, in combination with carboplatin, in patients who are not candidates for potentially curative surgery and/or radiotherapy.  
In order to in ject lung cancer directly, a minimally invasive procedure known as EBUS -TBNI  is proposed 
for this Phase [ADDRESS_975118] been demonstrated in numerous 
studies (Lu 2015, Mehta 2015, Mehta 2017).  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975119] been publ ished demonstrating the use, efficacy, and safety of ITU  injection 
of cytotoxic compounds. Cisplatin has demonstrated safety and efficacy when administered repeatedly 
on a weekly basis for 4 weeks at concentrations of 4 mg/m L and up to [ADDRESS_975120] Obstruction (MAO) ( Ҫelikoğu  2006, Mehta 2015). The same dose regimen of cisplatin 
was used in patients with recurrent lung cancer (≥ 1 site; tumor and/or nodal) in patients who had received prior radiotherapy, with good efficac y and safety (Mehta 2017).  
ITU liposomal paclitaxel (1 –  3 mg/m L concentrations) has been administered twice, one week apart, in 
combination with IV carboplatin and gemcitabine to 48 patients with unresectable stage III NSCLC with good efficacy and safety outcomes (Lu 2015).  
An ITU cocktail of drugs  was administered  to 93 patients with non -resectable MAO with primary or 
recurrent malignancy ( Ҫelikoğu  1997). The cocktail comprised 5 -FU (50 mg/m L), mitomycin (1 mg/m L), 
methotrexate (5 mg/m L), bleomycin (10 mg/m L), and mitoxantrone (2 mg/m L). Volumes of  1 -3 mL were 
injected every 1 -3 days until patency of the airways was restored; the average number of treatment 
sessions was 4 (range 1 – 6) over a 2 week period. In those with recurrent malignancy, ITU  injections 
were performed weekly for 6 –  10 weeks, and then every 1 –  [ADDRESS_975121] IV dose of paclitaxel of 175mg/m
2 BSA administered 
over 3 hours results in a C max of 3,650 ng/mL (Paclitaxel Package Insert). In the completed prostate 
cancer study, ITU  injection of a mean dose of 53.6 mg Nano Pac in a 15 mg/m L concentration resulted in 
Cmax of 19 –  20 ng/m L at the earliest recorded timepoint i.e.  [ADDRESS_975122] -injection. By [CONTACT_4475] 28, levels were 
still measurable at a m ean 0.057 ng/m L. (LLOQ = 0.025 ng/ml). Studies in ITU  injection of Nano Pac in 
pancreatic cancer and intralesional injection in pancreatic cyst are ongoing. However, i n the pancreatic 
cyst study, preliminary information shows an average dose of 84.37 mg Nano Pac in a 15 mg/m L 
concentration results in a plasma C max of 0.24 ng/m L two hours after injection. In the pancreatic cancer 
study preliminary information indicates an average dose of 53.375 mg Nano Pac in a 15 mg/m L 
concentration results in a C max of 3.1 9 ng/mL  one hour after injection.  
In this study, NanoPac will be administered at a concentration of 15 mg/mL directly into the tumor at a 
volume up to 20% of the total tumor and lymph node volume (s), up to a maximum of 40 mL. Subjects 
will therefore be en rolled with maximum tumor volumes 200 mL i.e. a maximum dose of 600 mg  or 10 
mg/kg in a [ADDRESS_975123].  Injection volumes up to 20% of tumor volume has been demonstrated to be 
safe in completed and ongoing studies with ITU injections of NanoPac into prostat e and pancreatic 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975124]. The maximum tumor (and node) volume for injection is therefore 200 
ml, which includes the combined volume of up to 2 lung tumor lesions (1 primary and 1 secondary) and 
metastatic lesions to local/regional lymph nodes.  
Since systemic absorption from ITU  injections of Nano Pac has been confirmed to be significantly low 
compared to IV infusions, a patient in this study administered a maximum single ITU treatment of [ADDRESS_975125] or ovarian 
cancer patient treated with a single IV infusion of 175 mg/m2 Taxol (assuming 100 % bioavailability for 
an ITU dose and linear PK ). 
Overall, the ITP injection studies provide the most relevant indirect evidence of expected toxicity when 
injecting Nano Pac directly into lung tumors. The observed effects were typi[INVESTIGATOR_715889], and likely secondary to leakage of paclitaxel. Systemic exposure at the highest dose of 28.8 
mg/kg is orders of magnitude below that achieved after conventional IV doses of paclitaxel. Local 
toxicity and systemic exposure after injection of lung tumors is expected to be similar to ITP injections.  
Given the systemic exposure after ITU  injection of prostate and pancreatic cancer, and pancreatic cyst, 
systemic exposure after 40 mL of ITU Nano Pac is expected to remain well below levels seen from IV 
chemotherapy.  
2.3 POTENTIAL RISKS AND BENEFITS  
2.3.1  KNOWN POTENTIAL RISKS  
There are no known potential  systemic risks from the ITU injection of NanoPac into lung tumors. The 
injection procedure itself includes risks related to the sedation and/or anesthesia required for the 
procedure, bronchospasm, hemorrhage from the injection, and possible leakage of Nan oPac from the 
injection site into the conducting airways.  
2.3.[ADDRESS_975126] -line treatment of locally advanced or metastatic 
NSCLC, in combination with carboplatin, in patients who are not candidates for potentially curative 
surgery and/or radiotherapy.  
3 OBJECTIVES AND PURPOSE  
The primary objective of this study is to evaluate the safety and t olerability of NanoPac injected into 
lung cancer lesions by [CONTACT_715919] -TBNI  on multiple (up to three ) occasions, each injection procedure 
administered [ADDRESS_975127] 
NanoPac injection ; with additional follow -up at weeks 38 and 52 . 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 22 of 61 Secondary objectives are:  
a) To describe the PK  of NanoPac when administered into the tumor(s) within the lung;   
b) To evaluate effect on progression free survival (PFS)  and overall survival (OS) in this population ; and  
c) to assess changes in the treated lesion (and lymph nodes) via CT scan imaging , histology, and 
immunochemistry  (IHC).  
[ADDRESS_975128] of c are (SOC) 
treatment, and will be enrolled after confirmation of adequate hematologic function (see Section 5.1).  
Subjects will receive NanoPac via EBUS -TBNI  to up to two lung lesions and their associated nodes (at the 
Investigator’s discretion) .  
Subjects  will be followed for safety during the [ADDRESS_975129] im aging at baseline (Screening), prior to 
each injection, and at Weeks 12, 18, 24, 38, and 52.  Subjects will also be assessed for quality of life 
(QOL) changes using the EQ -5D QOL questionnaire  and PFS. 
The lesion(s) to be treated must have been captured vi a imaging within [ADDRESS_975130] provide a demonstrated measurement (3 -dimension) for volume 
calculation. The volume calculation will be made using the ellipsoid formula:  V = 1/6 x π  x l x w x d.  
The tumor dia meter and volume measurement(s) will be determined from this imaging and recorded in 
the source and in the electronic data capture system  (EDC).  The CT imaging at Weeks  12, 24, 38,  and [ADDRESS_975131] purposes, for the secondary endpoint assess ment of tumor response  and PFS . 
Subjects will be enrolled to receive up to three injection procedures with 15 mg/m L Nano Pac, each 
injection 4 weeks apart, in up to two  parenchymal lung lesions and associated local/regional lymph 
nodes, up to a maximum of 2 0% of the tumor and lymph node volume, individually and/or in total. A 
maximum of [ADDRESS_975132] a primary or target lesion. Depending on the amount of NanoPac used for injection of the primary/target lesion, the 
remaining NanoPac may be administered into a second lung tumor lesion and/or metastatic lymph 
nodes up to a maximum  volume of 40 mL  of Nano Pac.  
For example, the sum of the volumes of lesions to be injected at baseline is 200 m L, from which the 
maximum volume allowed to be injected during any single bronchoscopic procedure is 40 m L. In the 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 23 of 61 case of a primary lesion of 6  cm diameter , the volume of the lesion will be 113.1 m L, allowing for an 
injection volume of 22.62 m L of 15 mg/m L Nano Pac. This leaves 17.38 m L (40 mL – 22.62 mL) of 
Nano Pac available for injection into local/regional  lymph nodes ( LNs) and/or the second tu mor where 
applicable. For a primary lesion with a [ADDRESS_975133]’s and/or a second tumor.  
The sequence of injections of tumor lesions will be prioritized according to the general principle of 
treating the primary lesion and associated metastatic node (s) before treatment of a second lesion and 
its associated metastatic node (s).  The sequence of prioritization is therefore the following:  
1) Primary tumor + local LN drainage i.e. N1 nodes first, then N2, then N3 if no contralateral 
nodules (M1a) ; 
2) Ipsilateral second tumor , where relevant, + local drainage i.e. N1 nodes first, then N2, then N3 if 
no contralateral nodules (M1a) ; or 
3) Contralateral second tumor (M1a except pleural/pericardial nodules or effusions), where 
applicable, + local drainage i.e. N1 nodes first, then N2.  
The Investigator may use his /her  discretion, on a subject -by-subject basis, to inject the entire tumor 
volume available or to use a lesser amount as he /she  deems necessary for each individual subject’s 
safety , subject to the above limits.   
Plasma samples will be taken on each day of inje ction, prior to injection and at 1, 2, and 4 hours after 
the start time of NanoPac injection, as well as at all other study visits up to Week 24 to characterize the 
PK of ITU NanoPac.  
Blood will also be drawn and sent to a central laboratory for flow cyto metric (FCM) analysis of immune 
markers prior to each injection (Day 1, Week 4, and Week 8) and at the follow -up visits occurring at 
Week 12, Week 18, and Week 24.  
Lung lesion biopsies for histopathology may  be obtained at the time of injection, prior to administration 
of NanoPac. Biopsies must not, however, be obtained from any lesions that are in proximity to cardiac or 
any vital neurovascular structures.  Routine processing for histopathology may be perform ed at the local 
institution; if only one biopsy is obtained, slides will be provided to the central laboratory for IHC 
staining and reporting, and a portion of the biopsy material will be stored frozen for batch shippi[INVESTIGATOR_86286] a central laboratory for evaluat ion of paclitaxel presence.   
4.2 ENDPOINTS  
4.2.1  PRIMARY ENDPOINT  
The primary endpoint will be safety and tolerability, as assessed by [CONTACT_117795] s, changes in vital signs, laboratory 
results, and changes in physical examination following NanoPac injection  up to W eek 24 . 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 24 of 61 4.2.2  SECONDARY ENDPOINTS  
The secondary endpoints will be:  
• Concentration of paclitaxel in the systemic circulation post -injection (as determined by [CONTACT_411212]);  
o If tissue biopsy samples are  obtained prior to any  NanoPac injection  tissue will also be 
evaluated for the presence of paclitaxel ; 
• PFS as assessed using (RECIST v1.1 ; Eisenhauer 2009 ) and OS to Week 52  with a focus on the week 
24 summaries ; 
• Assessment of tumor response (dimensions, volume) as determined by [CONTACT_715920], at Weeks 
12, 24, 38, and 52 compared to baseline ;    
o Any changes in characteristics of lesion/nodes as determined via CT scan.  
4.2.3  EXPLORATORY ENDPOINTS  
• Change in Eastern Cooperative Oncology Group ( ECOG ) Performance Status  at Weeks 12 and 24 
compared to baseline;  
• Changes in pain (as measured by [CONTACT_224968] [VAS]);  
• Changes in Q OL as measured by [CONTACT_20367] -5D Quality of Life Scale at baseline and at Weeks 4, 8, 12, 
18, 24, 38, and 52 ; 
• Immune markers will be assessed in the blood via FCM, and in the tissues via IHC.  
5 STUDY ENROLLMENT AND WITHDRAWAL  
 
5.1 PARTICIPANT INCLUSION CRITERIA  
Patients who meet the following criteria will be considered eligible for participation in the study:  
• Signed informed consent;  
• Age ≥18 years and able to tolerate the EBUS -TBNI  procedure;  
• Histologically/cytologically confirmed lung cancer.  Eligible subjects may include, for example: 
primary or recurrent non -resectable disease, locally advanced stages II and III with nodal 
disease, stage IV advanced disease  
• At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed 
using EBUS-TBNI; 
• Subject is not a candidate for surgery;  
• Has received or plan s to receive SOC  chemotherapy; adequate hematologic recovery must be 
confirmed according to the institution’s SOC ;  
• Performance Status (ECOG) 0 -2 at study entry;  
• Life expectancy of at least 6 months;  
• Adequate marrow, liver, and renal function at study entry;  
o ANC ≥ 1.5 x 1 09/L; 
o Hemoglobin ≥ 9.0 grams/dL ; 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 25 of 61 o Platelets ≥ 75 x 109/L; 
o Total bilirubin ≤ 1.5x institutional ULN ; 
o AST/ ALT ≤ 2.5x institutional ULN ; 
o Creatinine ≤ 1.5x institutional ULN ; 
• Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child -
bearing potential.*  
* Note: A female patient is considered to be of childbearing potential unless she has had a 
hysterectomy, is at least one year postmenopausal or has undergone tubal ligation. For the purposes of 
this study, adequate bi rth control includes at least one medically approved and highly effective method 
of birth control, defined as those which result in a low failure rate (i.e., < 1% per year) when used 
consistently and correctly, such as implants, injectables and oral contraceptives combined with the use 
of double condoms. Only male patients whose vasectomy has been confirmed by [CONTACT_649627] 
[ADDRESS_975134] be excluded from the study:  
• Significant cardiac  disease (Class III or IV per [LOCATION_001] Heart Association guidelines);  
• Active bacterial, viral, or fungal infections (including active AIDS, hepatitis B or hepatitis C);  
• Symptomatic central nervous system ( CNS) metasta sis which are neurologically unstable, or CNS 
disease requiring increase in steroid dose (treated metastatic disease and stable steroid use are 
not excluded);  
• Known hypersensitivity to study agent ; 
• Pregnant or breastfeeding women . 
5.[ADDRESS_975135]. The reason for 
wanting to withdraw will be documented in the source notes and in the EDC. The final study visit is 
planned for six months after NanoPac injection. For subjects wishing to pursue other treatment options 
(such as other clinic al trials) sooner than 12  months after NanoPac injection, the final study visit may be 
conducted sooner.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 26 of 61 • The Investigator , at their discretion , may elect not to administer the second or third injection or 
reduce the volume of the injection.  All subjects will be followed for safety for the duration of 
the trial unless informed consent is withdrawn.   It is very important that any events occurring be 
captured and followed for the safety of the subject.  
• Subjects may be non -compliant with the study protocol in a way that much of the data is not 
captured which would usually require withdrawal for non -comp liance; however, any data points 
missed would be considered “missing data.” A subject would not be withdrawn in this situation.  
 
• Clinical AE, laboratory abnormalities, or other medical conditions/situations may occur which 
would usually require withdrawal from a study. In this instance it is very important that all of 
these events be captured, followed, and documented, and therefore a subject would not be 
withdrawn but would continue to completion.  
Should the Investigator feel it to be in the best interest of the subject for them to be withdrawn from 
the study, or if another clinical trial is being considered for the subject, the Investigator will immediately 
contact [CONTACT_411221].  
5.4.[ADDRESS_975136] is withdrawn  before Week 24 they would complete all assessments for Week 24; if 
they withdraw after Week 24, they would complete the assessments which would be performed at 
either the Week [ADDRESS_975137]’s record.  
If a subject repeatedly misses study visits or remains non -compliant following NanoPac injection, and 
where the majority of data is not available, the option to replace that subject exists. However, the data that is collected from the non -compliant subject may still be used in the evaluations in this study.  
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
This study may be temporarily suspended  or prematurely terminate if there is sufficient reasonable 
cause. Written notification, documenting the reason for the study suspension or termination, will be 
provided by [CONTACT_715921]. If the study is prematurely termina ted or 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 27 of 61 suspended, the PI [INVESTIGATOR_715890].  
Circumstances that may warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants;  
o Routine Medical Monitoring determining a requirement for an ad hoc meeting of the 
Safety Review Committee (SRC), and/or routine SRC reviews, will allow for termination 
of study based on unacceptable risk, which will consider all safety evaluations and DLTs.    
• Insufficient compliance with protocol requirements;  
• Data that are not sufficiently complete and/or evaluable;  
• Determination of futility.  
The study may resume once concerns about safety, protocol compliance, and data q uality are addressed 
and satisfy the Sponsor, IRB, and/or FDA.  
6 STUDY AGENT  
 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  
6.1.1  ACQUISITION  
NanoPac will be manufactured by [CONTACT_411223], Inc. (Lawrence, KS) and provided for use in this study. Study 
agent will not be shipped to the study site until all regulatory documentation has been provided by [CONTACT_715922], at which time the study agent will be released for shipment. 
Shipment will be via courier, temperature contro lled at 59˚ to 86˚F (15˚ to 30˚C), and will occur prior to 
the site initiation visit. Study Agent will be shipped to the on -site pharmacy where it will be stored 
according to the conditions required (Section 6.1.3).  
6.1.2  FORMULATION, APPEARANCE, PACKAGING , AND LABELING  
NanoPac is presented as a white powder, provided in a sealed vial within a study kit.  
Study agent for all treatment groups will be supplied to the site in kits with one vial of Sterile 
Reconstitution Solution (1% Polysorbate 80, NF in 0.9% S odium Chloride for Injection, USP ), one 
NanoPac 306 mg powder -filled vial, and one pre -printed Instructions for Use (IFU) insert in a 2ct kit. The 
site will be responsible for providing 0.9% Sodium Chloride for Injection, USP and lactated Ringer’s 
solution .   
Kits will be provided for a once -only use and will be assigned to one subject only. Reconstitution will 
occur at the pharmacy on -site and the reconstituted study agent will be delivered for use by [CONTACT_3786]. An IFU insert will be provided in eac h kit and an instructional video will be provided to each 
site prior to the Initiation Visit, ahead of the first subject being enrolled. The IFU will contain information 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 28 of 61 on the reconstitution of the drug, the storage of the drug once reconstituted, the dos e withdrawal 
procedure, and the timeline permitted between reconstitution and use.  
The vial will be labelled to include details as follows:  
“NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension. 306mg per vial. Lot no.: 
XXXXXXXXXXX Caution: New Drug – Limited by [CONTACT_192321]. For single use only. 
Manufactured by: [CONTACT_715923]., [ADDRESS_975138], Lawrence, KS, [ZIP_CODE].”  
The carton will be labeled with information indicating the contents as follows:  
“Each kit contains: 1 vial of NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension, 306 mg 
per vial; 1 vial Sterile Reconstitution Solution for NanoPac Powder for Suspension, 7 ml per vial; 1 
instruction sheet for the reconstitution of the NanoPac dosi ng suspension and the dose withdrawal 
procedure.”  
6.1.[ADDRESS_975139] STORAGE AND STABILITY  
Prior to administration at the hospi[INVESTIGATOR_307]/clinic, the dry, sterilized NanoPac vials will be stored at the clinical 
site’s pharmacy, temperature controlled at 59˚ to 86˚F (1 5˚ to 30˚C).  
Once the NanoPac has been reconstituted, it will be delivered to the clinic for use. Reconstitution will 
occur in the pharmacy at the clinical site, and if the reconstituted agent is not being delivered 
immediately the syringe may be stored ac cording to the IFU until delivery. Each vial used and each 
syringe must be labelled with the subject’s ID and visit information for accountability purposes.  
6.1.[ADDRESS_975140] 24 hours prior to administration time.  
Once the drug has been reconstituted to the required volume at 15mg/mL the injection volume will be 
withdrawn, as described in  the IFU, from the vial (s) into one or more syringes up to a maximum volume 
of [ADDRESS_975141] injection . Actual amounts injected to the various lesions will be detailed in the source and in the 
EDC.   
The syringe (s) for administration will be labeled with the subject ID and the date and time of 
preparation.  
6.1.5  DOSING AND ADMINISTRATION  
Subjects will receive NanoPac on three occasions : on the Day 1, Week [ADDRESS_975142] institutional anesthetic procedure 
for the bronchoscopic procedure and injection of Nano Pac. At each injection visit tumor size (s) will also 
be measured using EBUS -TBNI, and the tumor (s) and node/nodal sizes recorded.  
EBUS -TBNI of the tumor(s) and node(s) within the lung will be used to inject 15 mg/mL NanoPac at a 
volume up to 20% of tumor and node volume for each individual lesion or metastatic node (as 
calculated in Section 4.1), up to a maximum volume of [ADDRESS_975143] injection procedure, the tumor volume  (lung and nodal lesions) will be calculated from the 
baseline CT information. The injection volume for  the second and third injection procedures should  be 
identical to the first injection procedure , but may be reduced per Investigator discretion . The volu me of 
Nano Pac injected, total and/or lesional, will at no time be increased beyond the maximum as calculated 
by [CONTACT_715924]( s) and may be reduced at discretion of Investigator .   
The stylet will be removed from a 22 -gauge fine needle aspi[INVESTIGATOR_1516] (FNA) needle and the needle filled 
with the study treatment, NanoPac, from the syringe provided. The needle will be luer locked into the 
accessory channel of the echoendoscope. Doppler ultrasound imaging will be used to verify lack of 
intervenin g vascular structures in path to tumor. NanoPac will be injected ensur ing that NanoPac is 
dispersed  evenly throughout the entirety of the tumor.  
6.1.6  ROUTE OF ADMINISTRATION  
NanoPac will be administered directly into the tumor(s) and node(s) within the lung via E BUS-TBNI .  
6.1.7  DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS  
Enrollment of the first three  subjects will be sequential. After the first subject has completed the [ADDRESS_975144] may be consented and undergo 
Screening activities  prior to SRC approval but may not be treated with Nano Pac until the SRC has given 
approval. The SRC may also determine at their discret ion, upon review of routine data, that 
dose/volume reduction is required for the remaining subjects in this study. This sequence of safety review will be repeated for the second and third subjects, after which enrollment will be open for all 
remaining subj ects.  
It is possible that the full 20% tumor (or lymph node) volume for a particular subject will not be able to 
be administered; the Investigator will determine this at the time of injection. In the event that not all of 
the calculated volume of NanoPac c an be administered, particularly with respect to the primary target 
lesion, the amount not injected will be available for use in other lesions or nodes  identified on the 
baseline CT , provided that the maximum volume injected into any lesion or node is not more than 20% 
of the volume of the lesion or node , up to a maximum of [ADDRESS_975145] not exceed 20% of lesion volume as calculated from the baseline 
CT scan . 
6.1.8  DURATION OF THERAPY  
NanoPac will be administered on up to three occasions 4 weeks apart.  
6.1.9  TRACKING OF DOSE  
Volume of NanoPac injected to any lesion or node will be documented within the source and the EDC.  
6.1.10  DEVICE SPECIFIC CONSIDERATIONS  
Not applicable.  
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  
The Investigator will maintain adequate records showing the receipt, dispensing, return, or other 
disposition of the study agent , including the date, quantity, batch or code number, and identification of 
subjects (number, initials) who received study medication.  
Accountability will be conducted using the records held by [CONTACT_649635], the individual vials, and the syringes.  No used vials or syringes will be kept for accountability 
purposes, they will be disposed of according to the standard operating procedures at the institutions.  
The Investigator will document the amount of NanoPac injected into each lesion and node, and any 
volume of NanoPac remaining unused, in the source document and in the EDC.  
Under no circumstances will the Investigator supply clinical material to other Investigators or clinicians 
or allow the supplies to be used other than as directed by [CONTACT_715925].  
7 STUDY PROCEDURES AND SCHEDULE  
 
7.1 STUDY PROCEDURES/EVALUATIONS   
7.1.1  STUDY SPECIFIC PROCEDURES  
The following procedures and evaluations will be done as part of this study.  
• Screening procedures/evaluations as described in Section 7.3.1 .  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 31 of 61 • Confirmation of adequate hematologic recovery (see Section 5.1 Participant Inclus ion Criteria) 
must be obtained prior to NanoPac administration and filed in the subject’s study record;  
• Comprehensive physical examination, including ECOG Performance Status assessment 
(Appendix A), and vital signs (blood pressure, heart rate, temperature,  body weight and height);  
• A CT scan will be conducted during the screening period prior to first injection, in order to 
calculate tumor and node volume(s). CT scans will also be conducted prior to the second and 
third injections (Weeks 4 and 8) and at foll ow-up visits at Weeks 12, [ADDRESS_975146] withdraw from the study at any time, a scan will be conducted as part of the E nd of 
Study procedures if possible. Additional imaging may be performed at the Investigator’s 
discretion as per i nstitutional SOC and all resulting images will be collected for the subject’s 
record.  The baseline CT scan wi ll be provid ed to the Medical Monitor for review/approval with 
the completed pre- injection form prior to first injection for all subjects.  All imaging will be  filed 
in the subject record and identifiers removed before images are shared with  the Sponsor.  
• Samples will be collected and processed for PK evaluation  (Section 7.2.2);  
• Samples will be collected and processed for routine clinical laboratory assessment ( Section  
7.2.1). 
• Samples  will be obtained and sent to a central laboratory for FCM evaluation of immune 
marke rs (Section 7.2.2) . 
• A biopsy specimen from the primary target lesion may  be obtained at each injection visit; 
biopsies must not, however, be obtained from any lesions that are in proximity to cardiac or any 
vital neurovascular structures.  If  available, a po rtion will be prepared on slides to be sent to a 
central laboratory for I HC assessments and a por tion will be stored frozen prior to bulk shipment 
to a central laboratory for evaluation of paclitaxel levels.  
• QOL will be assessed using the EQ -5D Q OL questionnaire  (Section 7.2.2) . 
• Pain will be assessed with the VAS at screening, on the days of NanoPac administration (pre - and 
post -injection), and at all other study visits  up to Week 24 . 
• NanoPac administered via EBUS -TBNI-guided fine needle injection  (Section 6.1.5) . 
7.1.[ADDRESS_975147] received or will be receiving concomitant SOC as 
required for their care; platelet and neutrophil recovery is required to meet inclusion criteria fo r 
participation.  
Following administration  of NanoPac, the care of the subject will be as dictated by [CONTACT_715926] (such as pain relief, 
additional clinic visits, etc.).  
Information on SOC and treatment post- injection(s) , until  the End of Study visit , will be captured as 
appropriate.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 32 of 61 7.2 LABORATORY PROCEDURES/EVALUATIONS  
7.2.1  CLINICAL LABORATORY EVALUATIONS  
Clinical laboratory assessments will be conducted at the local C LIA certified laboratory routinely used by 
[CONTACT_737].  
• The following laboratory tests will be performed at screening, on the days of NanoPac injection, 
2 weeks after each injection, and at the Weeks 12, 18 and 24  visits .  The samples to be collected 
are: sodium, potassium, chloride, carbon dioxide (CO2), calcium, phosphorus, glucose, blood 
urea nitrogen (BUN), creatinine, alkaline phosphatase, total bilirubin, direct bilirubin, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) , gamma -glutamyl transferase (GGT), 
lactate dehydrogenase (LDH), total protein, albumin, and calculated creatinine clearance;  
• Red blood cell count (RBC), hemoglobin (Hgb), hematocrit (Hct), white blood cell count (WBC) including differential, reticulocyte count, platelet count, and absolute neutrophil count (ANC);  
• Urinalysis including specific gravity, hydrogen ion concentration (pH), RBC, WBC, protein, and 
glucose; and  urine pregnancy test (if applicable at S creen ing, Week 12 and Week 24) ; 
• Prothrombin time  (PT), activated partial thromboplastin time (PTT) , and international 
normalized ratio (INR) . 
• Serology testing will be performed for HIV, Hepatitis B and Hepatitis C prior to first injection  
7.2.2  OTHER ASSAYS OR PROCEDURES  
PK samples will be taken at sche duled  injection  visits ( Day 1, Week 4, and Week 8 ), prior to NanoPac 
injection, and at 1, 2, and 4 hours +/ - [ADDRESS_975148] withdraw from the study at any time, a scan will be conducted as part of the End of 
Study procedures if possible. Additional imaging may be performed at the Investigator’s discretion and 
all resulting images will be collected for the subject’s record.   The baseline CT  scan wi ll be forwarded to 
the Medical Monitor for review/approval with the completed pre -injection form prior to first injection 
for all subjects.  All imaging will be collected for the subject’s record and identifiers removed before sharing copi[INVESTIGATOR_715891].  
Pain assessment will be conducted with the VAS  at all study visits  to Week 24 . On the day(s) of NanoPac 
admi nistration the pain assessment will be conducted prior to Nano Pac injection, and at [ADDRESS_975149] prior to discharge following the procedure to allow for residual anesthetic effects to wear off.  
QOL assessment will be conducted using EQ -5D QOL instrument at baseline, at each injection visit prior 
to the procedure, and again at Weeks 12, 18, 24, 38, and 52. 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 33 of 61 Blood samples will be collected for flow cytometric evaluation of immune markers at each injection visit 
and again at Weeks 12, 18, and 24.  
Biopsy specimens may  be collected at each  or any  injection visit and a portion will be prepared on slides 
for IHC assessment and a portion will be stored frozen for paclitaxel assessment.  
7.2.3  SPECIMEN PREPARATION, HANDLING, AND STORAGE  
PK samples will be drawn at the specified time/visit, prepared and  stored frozen on -site until batch -
shipped to Covance Laboratories (Madison, WI) for analysis. Procedures for processing for storage will 
be provided prior to study initiation.  
Biopsy specimens for paclitaxel assessment , when available,  will be stored froz en on -site until batch -
shipped to Covance Laboratories (Madison, WI) for analysis.   
Serum samples for routine laboratory assessments will be obtained at the specified time/visit and will 
be sent to the local CLIA certified laboratory for analysis. Results  will be sent to the Investigator for the 
source record and entry to the EDC.  
Blood samples for FCM will be drawn into tubes provided for this purpose, and shipped to NeoGenomics 
on the day the sample is obtained; samples may remain at ambient temperature until shipped.  
Biopsy specimens for IHC evaluation , when available,  will be sent to the site’s pathology laboratory for 
preparation of tissue block/ slides to be shipped to NeoGenomics . A manual will be provided by 
[CONTACT_715927].  
7.2.[ADDRESS_975150] be completed, documented and reviewed by [CONTACT_715928], within 28 days prior to NanoPac injection:  
• Written informed consent including comprehensive di scussion of the study schedule, 
procedures and subject protocol requirements;  
• Complete medical history, including review of previous medical records, and demographics;  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 34 of 61 • Review and documentation of lung cancer, including documentation of lesion size(s) as 
determined by [CONTACT_9661]; diagnosis and previous treatments including surgical and 
chemotherapeutic records. A copy of the pathology report confirming the diagnosis must be 
filed in the subject’s study record;  
• Review and documentation of all concomitant prescription and non -prescription medications;  
• Comprehensive physical examination, including ECOG Performance Status assessment (Appendix A), and vital signs (blood pressure, heart rate, temperature, body weight and height);  
• Visual analog scale for pain assessment;  
• Sample collection and processing for clinical laboratory assessments (Section 7.2.1);  
• Urine pregnancy test for women of child -bearing potential;  
• Imaging with CT  scan will be performed prior to the next study visit; the scan may be performed 
any time within [ADDRESS_975151] scan will be forwarded to the Medical Monitor for review/approval with 
the completed pre- injection form prior to first injection for all subjects.   
Visit dates will be scheduled/projected forward from the first injection visit at Day 1.  
Visits from Week [ADDRESS_975152] a +/ - one day window; Weeks 12, 18 and 24 will allow for a +/ - 
1-week window ; Weeks 38 and 52 will allow for a +/ - 2-week window  
7.3.2  DAYS OF NANOPAC INJECTION –  DAY 1, WEEK 4, WEEK 8  
Day 1:  All Screening assessments must have completed prior to this visit, and all results and 
inclusion/exclusion criteria must have been confirmed.  
All injection visits –  Day 1, Week 4, Week 8 , prior to the bronchoscopic procedure:  
• Subjects will complete an EQ -5D Q OL questionnaire  
• Comprehensive physical examination, including vitals and ECOG Performance Status assessment  
(Appendix A) ;  
• VAS for pain assessment will be completed pre - and post -injection.  Post -injection scale will be 
completed at the 4-hour PK sample timepoint.  
• AEs occurring in the period between S creening and this visit must be confirmed as either 
ongoing or completed. AEs occurring prior to the procedure will be considered history, and 
those occurring after NanoPac administration will be documented separately as TEAE, with a 
start date on or after administration.  
• Concomitant medication will be reviewed and updated as necessary;  
• Laboratory sample collection prior to injection, and processing for clinical laboratory 
assessments (Sectio n 7.2.1):  
o Routine safety laboratory work and blood sample for FCM  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 35 of 61  Coagulation laboratory assessment results must be confirmed to be within 
normal limits prior to injection if a biopsy is planned  
o PK samples pre -injection and 1, 2, and [ADDRESS_975153] ion 
• Imaging with CT scan will be performed prior to injections at Week 4 and Week 8  and may  be 
obtained up to  3 days prior to the scheduled injection visit.  
Subjects will receive NanoPac as described in Section 6.1.5 . Immediately prior to NanoPac injection , 
tissue biopsies will be obtained for routine histopathology at the site (if standard procedure) and for 
paclitaxel assessment and tissue block/ slide preparation for IHC assessment.  
7.3.3  FOLLOW -UP VISITS  
Follow up visits occur one and two weeks after each injection (Weeks 1, 2, 5, 6, 9, and 10) and then at Week 12 and at Week 18.  
At all follow -up visits the following are performed:  
• VAS for pain assessment w ill be completed ; 
• Vital signs will be assessed ; 
• A single PK sample will be collected ; 
• Concomitant medications will be updated ; 
• AEs will be updated . 
At Weeks 2, 6, 10, 12, and 18 routine safety blood samples will be obtained and sent to the local laboratory for assessment (Sectio n 7.2.1) .  A urine pregnancy test will be performed at Week 12 for 
women of child -bearing potential.  
At Weeks 12 and 18 the following additional assessments will be performed:  
• QOL questionnaire will be completed ; 
• An ECOG score will be obtained ; 
• A blood sample for FCM analysis of immune markers will be obtained ; 
• A CT scan will be performed  within the visit window . 
 
 
In the event that an Investigator or subject elects not to receive all three scheduled injections, not a ll 
study visits listed in the schedule of events are required. The list below clarifies what visits are to be 
conducted when injections are missed.  
− Week 4 Scheduled Injection Missed: Week 5 visit is not required ; Week [ADDRESS_975154] will then return at Week 8 for their next injection  if all criteria for receiving the injection 
are met . 
− Week 8 Scheduled Injection Missed: If Week 8 injection procedure is missed, the one- week 
follow -up (Week 9) is not required but the two -week follow -up (Week  10) is still required.  
− Week 4 and Week 8 Scheduled Injections Missed: If a subject misses the Week [ADDRESS_975155] passed since 
investigational drug administration. In this situation, Weeks 5 , 9, and 10 are not required . 
7.3.4  PRIMARY ENDPOINT  STUDY VISIT (WEEK 24, APPROXIMATELY 6 MONTHS)  
This primary endpoint  visit will be conducted at Week 24 ± [ADDRESS_975156] withdrawing prior to 
Week 24 all assessments as described for this visit would be conducted.  
Subjects may decide to withdraw participation prior to this point and at that time this visit should be 
conducted if possible. For some subjects the Week 12 (3 -month) or Week 18 study visit may serve as the 
final study visit, as this 6 -month visit will only be conducted for subjects still willing and able to undergo 
the assessments.  
At th is primary endpoint  study visit the following procedures will  be performed:  
• Comprehensive physical examination, including vitals and ECOG Performance Status 
assessment;  
• VAS for pain assessment will be completed ;  
• QOL questionnaire will be completed ; 
• Concomitant medications will be updated;  
• AE collection up to the Week 24 visit  (noted to be resolved or ongoing at this visit);  
• Sample collection and processing for clinical laboratory assessments (Section 7.2.1);  
o Routine safety laboratory work and blood sample for FCM ; 
o PK sample obtained;  
o Urine  pregnancy test for women of child -bearing potential;  
• Imaging with CT  scan  within the visit window . 
7.3.5  FOLLOW UP VISIT WEEK 38 AND END OF STUDY WEEK 52 
 
These visits are being conducted in subjects still willing and able to undergo assessments for the 
purposes of determining QOL, PFS, and OS.  
 
The following procedures will be performed:  
• Vital signs will be performed ; 
• ECOG will be assessed ; 
• QOL questionnaire will be completed ; 
• Imaging with CT scan  within the visit window ; 
• Concomitant medications – only those used as SOC lung cancer therapi[INVESTIGATOR_715892] . 
 
For any subjects withdrawing after the Week 24 visit , their withdrawal visit would include all 
assessments noted for these visits.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 37 of 61  
Week 38 and Week 52 visits will be performed with a visit window of +/ - [ADDRESS_975157] is withdrawn from the study between Week 24 and Week 52, the 
assessments for Week 52 will be conducted.  
7.3.6  UNSCHEDULED VISITS  
Any unscheduled visits will be docu mented in the source documents, and any assessments and/or 
evaluations performed will be noted and reviewed. The subject will undergo any other evaluations 
determined necessary by [CONTACT_609948]’s well -being. If the Investigator dee ms it 
necessary for blood work to be done, this information will be transcribed into the EDC, and any imaging assessments which may be performed will also be noted in the EDC.  
 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July  2021  CONFIDENTIAL  Page 38 of 61 7.3.7  SCHEDULE OF EVENTS TABLE  
 
  Screening6 Day 1  
Week 1    Week 4      Week 8          Week 24  Week 38  Week 52  
NanoPac  Week 2  NanoPac  Week 5  Week 6  NanoPac  Week 9  Week 10  Week 12  Week 18  (6 
months)  (9 
months)  (12 
months)  
Informed Consent  X                             
History1 X                             
Physical Exam X X     X     X         X     
Pain Assessment4 X X X X X X X X X X X X X     
QOL 
Questionnaire    X     X     X     X X X X X 
Vital Signs  X  X  X X X X X  X X X X X X X X 
ECOG2 X X      X       X     X X X X X 
Clinical 
Laboratory 
Tests8,9 X X   X X   X X   X X X X     
PK Samples 
(blood)3   X X X X X X X X X X X X     
Blood FCM 
analysis    X     X     X     X X X      
Tissue (biopsy) 
for IHC and 
paclitaxel    X     X     X               
Imaging (CT 
Scans)[ADDRESS_975158] scan will be conducted as part of the end of study procedures. Additional imaging may be performed at  the Investigat or’s discretion as per institutional 
SOC and all resulting images will be collected for the subject’s record.  
[ADDRESS_975159] for women of child -bearing potential at Screening, Week 12 and W eek 24 . 
9       Clinical laborato ry tests include hematology, chemistry, urinalysis and at screening includes serology  (Hepatitis A, Hepatitis B and HIV).  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 40 of 61 
 7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  
Sponsor acknowledges that EBUS -TBNI of NanoPac into the tumor(s) and node(s) within the lung, 
including the anesthesia necessary for the injection, may qualify as a sensitive procedure and as such 
should be mentioned in this section.  
7.5 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the  
electronic  Case Report Forms (eCRFs). For this protocol, a prescription medication is defined as a 
medication that can be prescribed only by a properly author ized/licensed clinician. Medications to be 
reported in the eCRF are concomitant prescription medications, over- the-counter medications, and non -
prescription medications.  
Although no interaction studies have been conducted using NanoPac, paclitaxel is metab olized by 
[CONTACT_9058] P450 isozymes CYP2C8 and CYP3A4 (Taxol Package Insert). Thus, there is a potential for 
drug interactions with concomitantly administered substrates (e.g., repaglinide and rosiglitazone), 
inhibitors (e.g., gemfibrozil), and inducers (e. g., rifampin) of CYP2C8. There is also the potential for 
paclitaxel to interact pharmacokinetically with CYP3A4 substrates (e.g., midazolam, buspi[INVESTIGATOR_5331], 
felodipi[INVESTIGATOR_050], lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, 
clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepi[INVESTIGATOR_050]).  
7.6 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES  
No precautionary medica tions, treatments, or procedures are included in this protocol; they may, 
however, be administered at the discretion of the Investigator, anesthesiologist, or the subject’s primary 
care provider or oncologist. All medications will be recorded.  
7.[ADDRESS_975160] be made aware of this as soon as possible.  
7.8 PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES  
Prophylactic antibiotics will be administered on the day of NanoPac injection and any other prophylactic medications will be administered according to the institution’s standard of care.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 41 of 61 
 7.9 RES CUE MEDICATIONS, TREATMENTS, AND PROCEDURES  
Rescue medications, treatments, and procedures will be performed according to the institution’s 
standard of care, and will be documented in the source documents and in the study data as needed.  
7.10  PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  
Not applicable.  
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
Safety assessments to be conducted in this study include:  
• AEs, collected at all study visits from the time of dosing  to Week 24 ; 
• Changes in concomitant medications;  
• Findings from physical examinations;  
• Changes in vital signs; and  
• Changes in laboratory parameters.  
Safety will be reviewed by [CONTACT_649640], and details 
will be confirmed at routine on -site monitoring visits. Additionally, SRC review  will be conducted as 
follows:  
• As described in Section 6.1.7, for only the f irst three subjects enrolled to the study, the SRC will 
conduct a review after each of the first three  subjects completes the [ADDRESS_975161]  
three subjects completes the 2 -week follow -up visit after their second injection of NanoPac.  
• The baseline redacted CT scan wi ll be forwarded to the Medical Monitor for review/approval 
with the completed pre -injection form prior to first injection for all subjects.   
• Thereafter, safety reviews will take place on a monthly basis during the conduct of the study. The Medical Monitor will review the data for each subject entered to the database on a monthly 
basis and communicate the summary findings to the SRC at each review.   
• The SRC may also convene at any other time if deemed necessary  or requested by [CONTACT_715929] . 
Included in the SRC’s review of the AEs and general study data pertaining to safety (such as laboratory 
results and questionnaire respon ses) consideration will be given to any adverse event that is considered 
related or possibly related to NanoPac and therefore is potentially a DLT. The definition of a DLT will be 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 42 of 61 
 made by [CONTACT_715930] [INVESTIGATOR_411206] . DLTs will, in addition, include the 
following:  
• ≥ Grade 3 febrile neutropenia;  
• ≥ Grade 3  non-hematological toxicity, unless clearly not attributable to the study agent;  
• Grade 3 diarrhea and vomiting lasting more than 72 hours, or Grade 4 diarrhea and vomiting;  
• Grade 4 neutropenia lasting 5 days;  
• Grade 4 thrombocytopenia;  
• Grade 4 biliary toxicity;  
• Concomitant elevation of AST/ALT 3x ULN and bilirubin 2x ULN (Hy’s Law)  
• Any life -threatening event (unless there is a clear alternative explanation that the event is not 
related with the procedure or the study agent  itself); and  
• Any clinically important event as defined by [CONTACT_12217].  
DLTs may result in removal of the subject from study treatment, however they will not be discontinued 
from the study follow -up procedures unle ss deemed to be in their best interest.  
 
Events of special interest (Section 8.4.4) will be specifically reviewed by [CONTACT_1689] , and the 
SRC review will provide and document oversight as detailed in the Safety Plan . 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended change in structure, function, signs, 
or symptoms temporally associated with the use of a medicinal product, whether or not related to the 
product. Undesirable changes in laboratory values should not be considered AEs unle ss they are 
considered symptomatic of a clinical condition or diagnosis, are evaluated as clinically significant, or 
require therapy. Worsening of a pre -existing condition is also considered an AE, as is the discovery of an 
abnormal finding during physical exam that was not included in the medical history. Clinical conditions 
attributable to disease progression will be considered AEs and reported on the eCRF.  
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
A Serious Adverse Event (SAE) is any adverse event  that meets at least one of following criteria:  
1) Is fatal;  
2) Is life -threatening, meaning the subject was, in the view of the Investigator, at immediate 
risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred  in a more serious form or progressed, might have caused death;  
3) Is a persistent or significant disability or incapacity;  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 43 of 61 
 4) Requires or prolongs inpatient hospi[INVESTIGATOR_059]. Inpatient hospi[INVESTIGATOR_123324] a 
hospi[INVESTIGATOR_649616] 24 h ours, or a hospi[INVESTIGATOR_715893] (non -diagnostic);  
5) Is a congenital anomaly or birth defect;  
6) Other important medical events may be considered a serious adverse experience when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent one of the outcomes as listed in #1 -5 in 
this definition.  
8.1.3  DEFINITION OF UNANTICIPATED PROBLEMS (UP)  
As this is a Phase 2 study, all unantici pated problems will be captured as either AEs or SAEs and will be 
defined and reported accordingly.  
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
8.2.1  SEVERITY OF EVENT  
Signs and symptoms will be graded by [CONTACT_118554] v  5 grades; Grades [ADDRESS_975162] unique clinical descriptions of severity for each AE based on the general guideline as follows:  
• Grade 1 -  Mild:  Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2 -  Moderate:  Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living  
• Grade 3 -  Severe:   Or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_715894]; disabling; limiting self- care activities of daily living  
• Grade 4 -  Life-Threatening:   Urgent intervention indicated  
• Grade 5 -  Fatal:  Death related to the adverse event.  
8.2.2  RELATIONSHIP TO STUDY AGENT  
The following five -point scale will be used by [CONTACT_715931]:  
• Definitely related: A clinical event (including laboratory test abnormality) occurring in a plausible 
time relationship to drug administration, and whi ch cannot be explained by [CONTACT_63400]. The response to withdrawal of the drug (de -challenge) should be 
clinically plausible. The event must be definitively associated pharmacologically, using a 
satisfactory re -challenge p rocedure, if necessary;  
 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 44 of 61 
 • Probably related: A clinical event (including laboratory test abnormality) with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease or other 
drugs or chemicals, and which follo ws a clinically reasonable response on withdrawal (de -
challenge). Re -challenge information is not required to fulfill this definition;  
 
• Possibly related: A clinical event (including laboratory test abnormality) with a reasonable time sequence to administra tion of the drug, but which could also be explained by [CONTACT_64758]. Information on drug withdrawal may be lacking or unclear;  
 
• Unlikely to be related: A clinical event (including laboratory test abnormality) whose temporal 
relationship to drug administration makes a causal relationship improbable (e.g., the event did 
not occur within a reasonable time after administration of the trial medication) and in which other 
drugs or chemicals or underlying disease provides plausible explanations (e.g., the subject’s 
clinical condition, other concomitant treatments);  
 
• Not related: An event for which sufficient information exists to conclude that the etiology of the 
event is unrelated to the study agent. An alternative definitive etio logy should be documented by 
[CONTACT_737].  
8.2.[ADDRESS_975163] but that in itself does not qualify as unexpected; review against information available and 
provided for the study agent is what will determine expectedness.  
Sponsor will be responsible for determining whether an AE is expected or unexpected. An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study agent, in the protocol and within the Investigator’s Brochure.  
 
8.[ADDRESS_975164] be followed until resolution or until the Investigator determines 
them to be stable and/or adequately managed.  
Subjects will be required  to spontaneously report any AEs. Study personnel will ask open -ended 
questions to obtain information about AEs at every visit. Date and time of onset and resolution (if applicable) of the AE will be documented.  
All SAEs must be followed until the event re solves or, in the opi[INVESTIGATOR_689], becomes stable.  
  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 45 of 61 
 8.4 REPORTING PROCEDURES  
8.4.1  ADVERSE EVENT REPORTING  
All AEs (whether or not attributable to the study agent) occurring during the [ADDRESS_975165] will be recorded on the eCRF. 
The following information will be recorded for all AEs:  
• Name [CONTACT_246805]/diagnosis/description;  
• Onset and resolution dates;  
• Severity;  
• Relationship to study agent;  
• Action taken;  
• Seriou sness.  
8.4.[ADDRESS_975166] be reported to 
the Medical Monitor immediately upon discovery of the event, using the SAE reporting form, by [CONTACT_715932], if necessary, by [CONTACT_309726]:  
[CONTACT_715946]: [EMAIL_7840]  
Phone : 805- 235-9193 
24-hour Emergency Contacts:  Gere diZerega, MD  or Antony Verco, MD  
    Medical Director   Medical Monitor  
    [PHONE_12627]    [PHONE_12628]  
The Study Manager  should be copi[INVESTIGATOR_715895] . 
The Sponsor will advise the Investigator regarding the nature of any further information or 
documentation that is required. The Investigator should provide the following documentation at the 
time of notification if available:  
• SAE Report Form;  
• Concomitant and support medication pages;  
• Relevant diagnostic reports;  
• Relevant laboratory reports;  
• Admission Notes;  
• Hospi[INVESTIGATOR_44458] (when available).  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975167] 24 weeks  of the study and meet the  criteria 
for an AE or SAE will be captured in the source documents and in the EDC, and in the case of an SAE, also 
on the formal reporting form designed to capture the required information. Reporting of these events 
will be in accordance with the rules ar ound AE and SAE reporting described in the protocol, including 
notification of the IRB and/or FDA as required.  
8.4.[ADDRESS_975168] will be signs of systemic toxicity due to paclitaxel exposure; this is not expected 
and is considered unlikely given the mode of administration. Events of interest include systemic adverse 
effects known to be caused by [CONTACT_114461] e.g. neutropenia, febrile neutropenia, sepsis, anemia, 
thrombocytopenia, and peripheral neuropathy. Local AEs of i nterest include chest pain (pleuritic and 
non-pleuritic, back, shoulder), shortness of breath , cough, wheezing, hemoptysis, 
pneumonitis/pneumonia, mediastinitis, Superior Vena Cava (SVC) syndrome, Horner’s Syndrome, and 
bronchopleural fistula.  
8.4.[ADDRESS_975169] before receiving any treatment (Section 5.1 Participant 
Inclusion Criteria) .  
Any pregnancy occurring in a subject or a subject’s sexual partner during the study or within [ADDRESS_975170] be reported to Sponsor as soon as the Investigator is aware of it. The 
pregnancy will not be considered an SAE; however, information on these pregnancies will be collected 
and followed for the outcome of the pregnancy and the health of the newborn.  
Any pregnancy complication or premature terminations including miscarriage, spontaneous abortion, or elective termination of a pregnancy for medical reasons will be reported as an SAE, as described in 
Section 8.4.2. Should the pregnancy result in a congenital anomaly or birth defect, a separate SAE report 
must be submitted. Furthermore, all neonatal deaths that occur within [ADDRESS_975171] received treatment will be followed to the completion 
of their participation to ensure all safety data is collected on all treated subjects.  
The Sponsor is responsible for notifying FDA of any temporary halts to the study or when a study is 
terminated; the Investigator will be required to notify the IRB accordingly.  
8.[ADDRESS_975172] 
physician  (Section 8.1 Specification of Safety Parameters) . 
All subject study data will be captured in an EDC system, allowing real- time access to ongoing safety and 
tolerability data.  
The SRC will convene to review the sub ject data, and a report will be generated outlining any safety 
concerns from the data available for review in the EDC.  Reviews will take place as described in Section 
6.1.[ADDRESS_975173]’s medical records, 
regulatory binder, study binder, eCRFs, and source documents as needed to assure that the conduct of 
the study is with in compliance.  
In addition, FDA or other government agencies may request an inspection following notification to the site. In such an event, the Investigator agrees to notify the Sponsor immediately of the request, and will 
allow Sponsor and inspectors to  review records.  
US Biotest will conduct a site initiation visit to provide the Investigator and their staff with a 
comprehensive overview of the protocol and study procedures and to review mutual obligations and 
requirements of regulatory authorities. A r egulatory file or binder containing required documentation 
will be kept at the site for reference and inspection.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975174]’s eCRF by [CONTACT_649643], to ensure 
adequate records of clinical supplies are maintained, and to assess the continued suitability of the investigational site. On completion of the study, the monitor will make a final assessment of the conduct 
of the study and inventory all clinical supplies to be returned to US Biotest.  
10 STATISTICAL CONSIDERATIONS  
 
10.1  STATISTICAL AND ANALYTICAL PLANS  
A formal Statistical Analysis Plan (SAP) will be prepared for this trial, and the SAP will be signed off prior 
to study database lock.  
10.2  STATISTICAL HYPOTHESES  
No formal statistical inference (i.e., “p -values”) will be applied. The results of this trial will be based on 
descriptive statistics only.  
10.3  ANALYSIS DATASETS  
In this safety and tolerability trial, all subjects who are enrolled and receive a dose of study agent will be 
included in the descriptive analysis.  
10.3.1  MISSING DATA  
Data will be presented as observed and no missing data imputation will be performed. A ll effort will be 
made to capture sufficient information to allow for medical interpretation of the results.  
The SAP will define intercurrent events (e.g.  not completing the full course of treatment (i.e. three injections), use of alternative medication, or stoppi[INVESTIGATOR_715896]); different strategies will 
be developed to address the possible impact on the ability to derive a reliable treatment- related 
estimate of each of the outcomes of interest.  
Given the small number of subjects and the descri ptive nature of summary statistics, it is recognized 
that looking at ‘sensitivity’ analyses will likely be limited to a variety of summary tables . 
10.4  DESCRIPTION OF STATISTICAL METHODS  
10.4.1  GENERAL APPROACH  
The focus of the trial will be on the safety and tolerability of the treatments. The general approach will 
be to highlight any trends that cause concern for the reviewing medical monitoring team (i.e., DLTs). 
Events that are related to the mode of administration will be presented separately from thos e that may 
have a relationship to the actual study medication.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 49 of 61 
 10.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
Not applicable. The primary objective is to evaluate the safety and tolerability as demonstrated by [CONTACT_117795], 
changes in laboratory assessments, ph ysical examination findings and vital signs.  
10.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
Secondary endpoints will be summarized descriptively. These will include supportive information to provide context for the dose(s) chosen to move forward for future study, as follows:  
• Concentration of paclitaxel in the systemic circulation post -injection (as determined by [CONTACT_482536]);  
• Tumor response (RECIST as per Eisenhauer 2009);  
• Reduction in pain (as measured by [CONTACT_198064]) . 
 
See also Section 10.4.11, Exploratory Analyses, for further details.  
10.4.4  SAFETY ANALYSES  
[IP_ADDRESS]  ADVERSE EVENTS  
AEs recorded during the trial will capture medically relevant changes found during the physical exam, 
and medically relevant changes in vital signs and laboratory analytes found during the course of the trial. 
In addition, spontaneously reported or observed events will be reco rded.  AEs will be recorded from Day 
[ADDRESS_975175] number and cumulative dose to date, investigator term, Medical Dictionary for Regulatory Activities  (MedDRA ) coded term, date/study day (from initial treatment) for onset and 
cessation, severity (using the NCIC severity grading), and relationship to study medication. Only the TEAE 
will be tabulated.  
The primary safety analysis and clinical study report will be based on the data at the [ADDRESS_975176] recent version of MedDRA, signed off by [CONTACT_1689], 
and presented by [CONTACT_6657]. All AE and abnormal laboratory variables will be assessed according to the NC I-CTCAE v  5.0 grading system. The number of subjects reporting and 
number of events reported will be presented in frequency tables (overall, by [CONTACT_2236], by [CONTACT_715933]). AE s of special interest will be defined in the SAP and presented sep arately. The criteria 
for the most frequently reported events will be determined in the SAP after reviewing the data . 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 50 of 61 
 [IP_ADDRESS]  LABORATORY ANALYTES  
Quantitative laboratory data will be summarized as mean values and change from screening scores (i.e., 
change  = time point- screening) for each sampling time point. For tests with normal range provided, the 
clinical status and its change from screening (Normal/High Abnormal/Low Abnormal) will be 
summarized using shift tables. Analytes of particular interest (e.g.,  hematological tests) may be graphed 
by [CONTACT_1130]; these special analytes will be confirmed in the SAP.  
[IP_ADDRESS]  VITAL SIGNS  
Vital signs (systolic and diastolic blood pressure, heart rate, temperature and body weight) will be 
tabulated and mean raw values an d changes from baseline scores (change = baseline -visit) where 
baseline is the last measurement prior to the study agent application, for each treatment group.  
[IP_ADDRESS]  ECOG  
The ECOG scale will be tabulated as defined in the  SAP using shift tables to summa rize and highlight and 
changes in category across the visits.  
10.4.5  ADHERENCE AND RETENTION ANALYSES  
All subjects who enter the trial will be accounted for and any reasons for early termination noted –  
including disease progression.  
10.4.6  BASELINE DESCRIPTIVE STATISTICS  
Complete demographic and baseline data will be tabulated. The medical history, which will be coded in 
MedDRA, will be presented. The disease history data, with a focus on the previous treatment and 
current staging, and the i nformation collected on the procedure to apply the treatment will also be 
summarized.  
10.4.7  PLANNED INTERIM ANALYSES  
• There are no formal interim analyses planned. There will be an ongoing safety and tolerability 
review by [CONTACT_715934] S ection 
8.  
[IP_ADDRESS]  SAFETY REVIEW  
Safety Review is described in Section 8.1.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 51 of 61 
 [IP_ADDRESS]  EFFICACY REVIEW  
Imaging with CT  scan will occur within four weeks prior to the injection procedure (, at Weeks 4, 8, 12, 
18, 24, 38, and 52, or at any time deemed to be required by [CONTACT_093].   
These results will be summarized and changes from the pre -dosing measurements highlighted.  
10.4.8  ADDITIONAL SUB -GROUP ANALYSES  
Subjects who perform particularly well (i.e., experience minimal AEs) may be compared to those who 
perform more poorly. This topic, and the criteria for defining each group, will be detailed in the SAP.  
10.4.9  MULTIPLE COMPARISON/MULTIPLICITY  
Not applicable, as no inferential analyses will be employed.  
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  
 
All data collected in the eCRF will at a minimum be listed; listings will support the tabulated 
data/outcomes.  
10.4.11  EXPLORATORY ANALYSES  
PK pa rameters (i.e., AUC, C max, Tmax) will be calculated based on the plasma concentration data for the 
first [ADDRESS_975177] plots of concentration across time, if the 
data is amenable to these concepts. The final decision will be made after a review of the data and recorded in the SAP.  
Pain assessment scores will be summarized as mean values by [CONTACT_715935].  
QOL will be measured using the validated EQ -5D Q OL instrument  
Flow cytometric analysis of blood samples and ICH evaluation of slides  will be conducted by 
[CONTACT_715936] (central laboratory) and they will be responsible for providing reports of these findings.  
These findings may be presented in a standalone report which will be integrated into the Clinical Study  
Report (CSR).  
10.4.12  CONCO MITANT MEDICATION  
All medication taken during the trial will be, at a minimum, listed with the start and stop dates. For this 
small clinical trial, the medications will not be coded using the WHO Drug Dictionary.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 52 of 61 
 10.5  SAMPLE SIZE  
Defining the primary endpo int explicitly requires understanding the primary purpose of the study. If, in 
this case, the primary purpose of the study is safety, then the incidence of DLTs would be an appropriate 
endpoint. When choosing events that will qualify as DLTs, it’s importan t to consider the rarity of events 
given the small number of subjects. For example, if a particular AE  is known to occur in only 1% of 
subjects, there is an 16.5% chance it will appear in a particular cohort of 18 subjects. If the event only 
occurs in 5% o f patients, there is only a 60.3% chance it will appear in a given [ADDRESS_975178] cohort, and for 
an event with a base occurrence rate of 10%, the probability of observing at least one event will be 85%. So, rarity is a factor that should be considered when de ciding which adverse reactions to include as part 
of the endpoint. Estimates were obtained using the “confidence interval for probability of observing a 
rare event” calculation in nQuery Advisor version 8.3.    
10.6  MEASURES TO MINIMIZE BIAS  
10.6.1  ENROLLME NT/ RANDOMIZATION/ MASKING PROCEDURES  
Not applicable.  
10.6.2  EVALUATION OF SUCCESS OF BLINDING  
Not applicable.  
10.6.3  BREAKING THE STUDY BLIND/PARTICIPANT CODE  
Not applicable.  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
An eCRF is required an d must be completed for each consenting and enrolled subject by [CONTACT_715937]. All data in the eCRF must reflect the corresponding source document. Any corrections to entries made on the eCRF must be documented in a valid audit trail. Only data required 
by [CONTACT_715938].  
The Investigator must maintain adequate and accurate source documents on which the eCRFs for each subject are based. They will be separate and distinct from the eCRFs. These records should include 
detailed notes on:  
• The medical history prior to the subject’s involvement in the study;  
• Date of informed consent;  
• The basic identifying information that links the subject’s medical record with the eCRFs;  
• The results of all diagnostic tests performed, diagnoses made, therapy provided, and any other data on the condition of the subject;  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 53 of 61 
 • The medical condition during the subject’s involvement in the study;  
• All AEs;  
• The subject’s exposure to the study medication;  
• The subject’s exposure to any concomitant therapy;  
• All relevant observations and data on the condition of the subject throughout the trial;  
• Justification for all entries in the subject’s eCRF.  
[ADDRESS_975179] to its accuracy, authenticity, and completeness.  
The EDC application being used in this study is TrialMaster® version 4.2.1 from OmniComm System s. 
TrialMaster studies are hosted from a state -of-the-art data center with rigorous physical and electronic 
security. All data is backed up daily to Iron Mountain, in Ohio and is also backed up to a hurricane -proof 
bunker in Fort Lauderdale, [LOCATION_012]. OmniC omm has achieved certification with European “Safe Harbor” 
regulations, meaning that all necessary measures are in place to protect patient confidentiality even 
with the data being stored in a US data center. The data management and statistical CRO, McDoug all 
Scientific Ltd., ensures that the development of the eCRF follows their SOPs which are based on the 
Systems Development Life Cycle (SDLC) methodology. Access to the system is restricted by [CONTACT_595177]; these are controlled by [CONTACT_715939]. All personnel using the system will 
be trained and the training documented. All changes to the database are recorded in an audit trail. The 
database will be locked when all outstanding queries have been addressed, all agreed -to data is marked 
as source -verified, and the PI [INVESTIGATOR_609922].  
All software applications used in the collection of data will be properly validated following standard computer system validation that is compliant with all regulatory requirements.  
13 ETHIC S/PROTECTION OF HUMAN SUBJECTS  
 
13.[ADDRESS_975180]  
Before the start of the study, the study protocol, informed consent form and/or other appropriate 
documents will be submitted to the IRB and/or the authorities in accordance with local legal 
requirements. It is the respo nsibility of the Investigator to assure that all aspects of the IRB review are 
conducted in accordance with current regulations. US Biotest and the Investigator must inform each 
other in writing that all ethical and legal requirements have been met before the first subject is enrolled 
in the study.  
Amendments to the protocol will be subject to the same requirements as the original protocol. All changes to the consent form will be IRB -approved; a determination will be made regarding whether 
previously consented participants need to be re -consented.  
13.3  INFORMED CONSENT PROCESS  
13.3.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
Subjects being considered for participation in this study will be provided an informe d consent form (ICF) 
to read and sign before being permitted to participate. The ICF will describe the study agent and any 
prior findings from previous studies; study procedures including the timing of study clinic visits and their 
responsibilities to adhe re to those timelines; any risks which may be associated with the study agent or 
the procedures being carried out in the study; and all other items required under [ADDRESS_975181] enrolled in the study, in accordance 
with the U.S. Food and Drug Administration (FDA) regulations [ADDRESS_975182] 
or his/her guardian or legal representative before any activity or treatment is undertaken which is not 
part of routine care. This includes, but is not limited to, the performance of diagnostic or therapeutic 
procedures and the administration of study agent. The draft version of the informed consent document 
will be modified by [CONTACT_715940].  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975183] be maintained on file at 
the study site and be made available for review during monitoring visits and site audits.  
13.4  PARTICIPANT AND DATA CONFIDENTIALITY  
All local legal re quirements regarding data protection will be enforced. All study findings and documents 
will be regarded as confidential. The Investigator and members of his/her research team must not 
disclose such information without prior written approval from US Biotest.  
The anonymity of participating subjects must be maintained to the extent required by [CONTACT_2371]. Throughout 
documentation and evaluation, the subjects will be identified on eCRFs and other documents submitted 
to US Biotest by [CONTACT_73976], birth date, and subject number. The subjects will be told that all study 
findings will be stored and handled in strictest con fidence, according to legal requirements, and that 
authorized research Investigators and agents of the FDA, the NCI, and authorized personnel of US 
Biotest have the right to inspect their medical records.  
13.4.[ADDRESS_975184] access at the site prior to 
shippi[INVESTIGATOR_715897]/assessment. Samples will be stored using codes assigned by [CONTACT_715941].  
Samples will only be retained until analysis is complete, after which they will be disposed of according to 
the laboratory SOPs. No samples will be retained for any future use.  
Data will be kept in password -protected computers. Only Investigators and those delegated 
responsibility on the Delegation of Authority Log will have access to the samples and data.  
Copi[INVESTIGATOR_715898] a secure cabinet with controlled access 
and held for review until archiv ing of the study documents, at which time the redacted imaging data will 
be archived together with the Trial Master Filed.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975185] (EMR) 
data management system that is [ADDRESS_975186]’s 
official electronic study record.  
The EDC application being us ed in this study is TrialMaster® version 4.2.1 from OmniComm Systems. 
TrialMaster studies are hosted from a state -of-the-art data center with rigorous physical and electronic 
security. All data is backed up daily to Iron Mountain, in Ohio and is also backe d up to a hurricane -proof 
bunker in Fort Lauderdale, [LOCATION_012]. OmniComm has achieved certification with European “Safe Harbor” 
regulations, meaning that all necessary measures are in place to protect patient confidentiality even 
with the data being stored i n a US data center. The data management and statistical CRO, McDougall 
Scientific Ltd., ensures that the development of the eCRF follows their SOPs which are based on the Systems Development Life Cycle (SDLC) methodology. Access to the system is restricted  by [CONTACT_595177]; these are controlled by [CONTACT_411256]. All personnel using the system will 
be trained and the training documented. All changes to the database are recorded in an audit trail. The 
database will be locked when all outstan ding queries have been addressed, all agreed -to data is marked 
as source -verified, and the PI [INVESTIGATOR_609922].  
Data recording must follow the instructions described in the eCRF Completion Guidelines. The PI [INVESTIGATOR_715899]. The PI [INVESTIGATOR_126985], as identified on the Delegation of Responsibilities Log (and included on Form FDA 1572), must 
electronically sign the completed eCRF to attest to the accuracy, a uthenticity, and completeness of the 
data.  
The database will be locked when all outstanding queries have been addressed, all agreed -to data is 
marked as source -verified, and the PI [INVESTIGATOR_609922].  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -[ADDRESS_975187] maintain study documents:  
• For a minimum of two years following the date the marketing application (NDA) is approved for the 
indication for which the drug was investigated;  
• For a minimum of two years following the release date of the final report, if no marketing 
application is to be filed, or if the marketing application is not approved for the indication o f which 
the drug was investigated or is discontinued and FDA has been notified; or,  
• For a minimum of [ADDRESS_975188] obtain the Sponsor’s writte n permission before transferring or disposing 
of any records.  
14.3  PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), or 
FDA or IRB requirements. The noncompliance may be either on  the part of the participant, the 
Investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by 
[CONTACT_3483].  
These practices are consistent with ICH E6:  
• 4.5:  Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1:  Quality Assurance and Quality Control, Section 5.1.1  
• 5.20:  Noncompliance, Sections 5.20.1, and 5.20.2.  
It is the responsibility of the s ite to use continuous vigilance to identify and report deviations as soon as 
possible after occurrence and identification of the protocol deviation. All deviations must be addressed in study source documents, and reported to the Sponsor and the Data Manage ment group.  
Protocol deviations must be sent to the local IRB per their guidelines. The site PI/study staff is 
responsible for knowing and adhering to IRB requirements.  
Serious non -compliance on the part of the site, and an inability of the Sponsor to br ing the site back into 
compliance, will be reported to FDA in accordance with their requirements.  
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 58 of 61 
 14.4  PUBLICATION AND DATA SHARING POLICY  
By [CONTACT_33351], the Investigator agrees with the use of results of the study for the 
purposes of nati onal and international registration, publication, and information for medical and 
pharmaceutical professionals. If necessary, the authorities will be notified of the Investigator's name, 
address, qualifications, and extent of involvement. The Sponsor will prepare an integrated 
clinical/statistical report. Publication/presentation of data is not allowed without explicit permission 
from US Biotest, Inc. Submission of data for publication/presentation will be coordinated and approved 
by [CONTACT_609968].  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any 
research project that pr ospectively assigns human subjects to intervention or concurrent comparison or 
control groups to study the cause -and-effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical procedures, devices,  behavioral treatments, 
process -of-care changes, and the like. Health outcomes include any biomedical or health -related 
measures obtained in subjects or participants, including PK  measures and AE. The ICMJE policy, and the 
Section [ADDRESS_975189] that is appropriate to their participation in the trial.  As required by [CONTACT_8415], a Financial Disclosure Form 
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 59 of 61 
 will be completed by [CONTACT_715942] 1572 for this study at the site, the original will 
be filed in the TMF, and a copy will remain in the site’s regulatory binder.  
[ADDRESS_975190] Obstruction. Postgrad Med J 1997; 73: 159 -162.  
 Celikoglu F, Celikoglu SI, York AM, Golberg EP. Intratumoral administration of cisplatin through a bronchoscope followed by [CONTACT_715943] -small cell o bstructive lung cancer. 
Lung Cancer. 2006 Feb;51(2):225- 36. Epub [ADDRESS_975191] R, et al. New response evaluation 
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228- 47. 
 
Lu B, Sun L, Yan X, Ai Z, Xu J. Intratumoral chemotherapy with paclitaxel liposome combined with 
systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non -
small cell lung cancer. Med Oncol. 2015 Jan;32(1):345. doi: 10.1007/s12032- 014-0345- 5. Epub 2014 Nov 
28. 
 
Mehta HJ, Begnaud A, Penley AM, Wynne J, Malhotra P, Fernandez- Bussy S, Cope J , Shuster JJ, Jantz MA. 
Restoration of Patency to Central Airways Occluded by [CONTACT_715944]. Ann Am Thorac Soc Vol 12, No 9, pp 1345 –1350, Sep 2015.  
 
Mehta, H.J., Jantz, M.A. Endobronchial Ultrasound -guided Intratumoral Injection of Cisplatin for the 
Treatment of Isolated Mediastinal Recurrence o f Lung Cancer. J. Vis. Exp. (120), e54855, 
doi:10.3791/[ZIP_CODE] (2017).  
 
Taxol
® (paclitaxel) Injection Package Insert. Bristol -Myers Squibb Company. Rev July 2011.  
 
Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin DS, Schulz TK, et al. A phase I study of 
intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer 
Chemother Pharmacol. 2015 May;75(5):[ADDRESS_975192] 2019; 156 (3): 56 2-570.   
Intratumoral Injection of NanoPac in Subjects with Lung Cancer                   Protocol NANOPAC -2020 -01 
NanOlogy, LLC                                         Version 4.0 
 
7 July 2021  CONFIDENTIAL  Page 61 of 61 
 APPENDIX A: ECOG PERFORMANCE SCALE  
 
Patient performance status will be graded according to the Eastern Cooperative Oncology Group (ECOG) 
scale* as described below.  
 
Grade  ECOG PERFORMANCE STATUS DESCRIPTION  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours  
3 Capa ble of only limited selfcare, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair  
5 Dead  
 * As published in Am. J. Clin. Oncol.:  
 Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649 -655, 1982.  
 